

CURRICULUM VITAE

KEITH M. OLSEN, PHARM.D., FCCP, FCCM
Dean and Professor
07/21/2021

PERSONAL

Address

Office: College of Pharmacy
University of Nebraska Medical Center
986120 Nebraska Medical Center
Omaha, NE 68198-6120
Phone: (402) 836-9273
Cell: (402) 681-5070
E-mail: keith.olsen@unmc.edu

Residence: 5829 S. 119th Plaza
Omaha, NE 68137

Citizenship United States of America

EDUCATION

Bachelor of Science Wayne State College, (Chemistry; cum laude) August
1973 through May 1977

Doctor of Pharmacy University of Nebraska Medical Center July 1977
through June 1980

POST-DEGREE AND CONTINUING EDUCATION

ASHP Residency University of Nebraska Medical Center in Clinical
Pharmacy July 1980 through June 1981

APPOINTMENTS

Academic

Dean, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE.
January 2019 –

Dean, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR. November 2015 – January, 2019

Professor with Tenure, University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, AR 2015 – 2019

Graduate Faculty appointment, University of Arkansas for Medical Sciences, 2016-2019

Graduate Faculty appointment, University of Nebraska Medical Center, 2011-2015, 2019 -

Chair, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, January 15th, 2007- 2015

Professor of Pharmacy (with tenure), College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, July 1st, 2004-2015

Associate Professor of Pharmacy, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, October 1st, 1993 – June 30th, 2004

Director Clinical Pharmacokinetics Laboratory and Monitoring Service - College of Pharmacy, University of Arkansas for Medical Sciences May, 1992 – October, 1993

Associate Professor (with tenure) of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, July, 1990-1993

Assistant Professor of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas October, 1985 – June, 1989

Instructor, School of Nursing (formerly St. Anthony's School of Nursing), Oklahoma City University, Oklahoma City, Oklahoma July, 1981 – September, 1985

Assistant Professor of Pharmacy Practice, Southwestern Oklahoma State University, Weatherford, Oklahoma July, 1981 – September, 1985

Professional

Manager, Education and Research, Department of Pharmaceutical and Nutrition Care, The Nebraska Medical Center, Omaha, Nebraska, June, 2010 - 2015

Clinical Pharmacy Specialist (Critical Care), University Hospital, University of Nebraska Medical Center, October, 1993 – 2015, 2019 -

Critical Care Medicine (CCM) Team, University Hospital, University of Nebraska Medical Center, October, 1993 – 2015, 2019 -

Clinical Consultant - Nutrition and Research, J.L. McClellan Veteran's Administration Medical Center, Little Rock, Arkansas July, 1986 – September, 1993

Poison Information Consultant, Arkansas Poison and Drug Information Center College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas January, 1986 – July, 1988

Clinical Pharmacy Specialist (Critical Care), University Hospital of Arkansas, October, 1985 – September, 1993, 2015 - 2019

Nutrition Support Team Pharmacist, University of Hospital of Arkansas, October, 1985 – September, 1993

Critical Care Team, University of Hospital of Arkansas, October, 1985 – September, 1993

Clinical Pharmacokinetics Service, The University of Arkansas for Medical Sciences College of Pharmacy and The University Hospital of Arkansas, October, 1985 – September, 1993

Clinical Residency Consultant, J.L. McClellan Veteran's Administration Medical Center, Little Rock, Arkansas July, 1989 – September, 1993)

Consultant - Forensic Toxicology, Pulaski County Coroner's Office, Little Rock, Arkansas (July, 1987 – September, 1993)

Clinical Pharmacist Hillcrest Medical Center, Tulsa, Oklahoma, April, 1985 - September, 1985

Clinical Pharmacist St. Anthony Hospital, Oklahoma City, Oklahoma, July 1981 - April 1985

Pharmacy Intern Poison Control Center, Omaha, Nebraska, May 1979 - June 1980

Pharmacy Intern, Children's Memorial Hospital, Omaha, Nebraska, May 1979 through June 1980

CERTIFICATIONS AND LISCENSES

State of Nebraska – Pharmacist #9279
State of Arkansas – Pharmacist PD 07266

GRANT/CONTRACT SUPPORT

Drug Information Consulting Services; RFA Solicitation Number: FDA_18-233-1194887_FNO, Food and Drug Administration and National Center for Toxicological Research-FDA, \$909,013.05 PI Keith M. Olsen, Howell Foster, Amy Franks, Awarded March 05, 2018

IDeA States Pediatric Clinical Trial Network (ISPCTN), NIH ECHO \$41.8 million, Jeannette Lee and Charlotte Hobbs (PI), CO-I Keith Olsen (10% effort), 2016-2021

Evaluating Patient Medical and Economic Outcomes of Point-of-Care Molecular Diagnostic Testing: A Randomized Controlled Trial in Group A Streptococcal Pharyngitis. Roche Molecular Diagnostics. February, 2016-2018, Investigator initiated grant, \$125,000, Co-investigator with Don Klepser, PhD (PI).

Development of an Orthopaedic Osteomyelitis Implant Model. College of Pharmacy Seed Grant, \$25,000, May, 2013, Co-PI with Dr. Dong Wang

Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA3CT), NIH RO1-AG037120-01A1, \$2,914,152.00, 2011-2015, co-investigator; PI: Tim Baxter, MD

Estimation of the incidence of ventilator associated pneumonia caused by pseudomonas aeruginosa study (PAB05). Sanofi Pasteur, 2011-2012, \$59,047, PI

An observational prospective registry to identify demographic and clinical characteristics of patients hospitalized with euvolemic and hypervolemic hyponatremia and assess the comparative effectiveness of available treatments and the impact on resource utilization. Otuska, \$16,695, 2011-2012, PI

Awakening-Breathing Coordination, Delirium and Early Mobility (ABCDE) Protocol: A Nurse Led, Inter-professional, Multi-component, and Plan for Managing Delirium in the Critically Ill Adult. Robert Wood Johnson Foundation, 2010-2012, \$300,000, Balas M (PI), **Olsen KM** (Co-I)

Efficacy of superoxide dismutase polymer conjugates for the treatment of oxidative damage induced by traumatic brain injury. COBRE Pilot Grant, University of Nebraska

Medical Center, Center for Drug Delivery and Nanomedicine, 2010-2011, \$50,000, Kelso M (PI), **Olsen KM** (CO-I)

Effect of rosuvastatin response in healthy subjects: potentials mechanisms of anti-inflammatory effects. CCRT Pilot Grant Fund – The Nebraska Medical Center and University of Nebraska Medical Center, 2009-2011, \$13,370, McGuire T (PI), **Olsen KM** (CO-I)

Evaluation of pharmacodynamic attainment with vancomycin in treatment of infections caused by Staphylococcus aureus. CCRT Pilot Grant Fund – The Nebraska Medical Center and University of Nebraska Medical Center, 2009-2011, \$46,030, **Olsen KM** (PI)

Comparison of telavancin, vancomycin and ceftriaxone efficacy and pharmacodynamics in a rat model of pneumococcal pneumonia. **Olsen KM** (PI), Gentry-Nielsen MJ, Preheim LC. 2009-2011, \$125,000, Astellas Pharma

Effect of statins on LPS response in healthy subjects: Potential mechanisms of improved survival in patients with sepsis. McGuire TR (PI), Dobesh P, **Olsen KM**, 2009-2011, \$71,670, Astra-Zeneca

Correlates and Economic Outcomes of Enteral and Parenteral PPI Use in the ICU and after ICU discharge , KM Olsen (PI), J Sankaranarayanan, 2008-2011, \$54,500, Takeda, Inc.

Comparison of Microbiologic Growth in Four Intravascular Devices. Carmel Pharma, 2008-2011, \$108,943, Keith M. Olsen, PI, Massoumi F (CI), Nielsen, M (CI)

American Society of Health-System Pharmacists symposium: "The Pharmacists and SIP and SCIP, ASHP, 2006, \$4,500, Keith M. Olsen, PI

Comparison of daptomycin and daptomycin derivative (CU-0573) to vancomycin and linezolid in a rat model of MRSA pneumonia. Cubist Pharmaceuticals, Inc., 2006-2007, \$125,000, Co-Investigator with Laurel Preheim, MD, Martha Nielsen, PhD (PI)

Comparison of tigecycline, vancomycin and linezolid for the treatment of Staphylococcal pneumonia in a rat model. Wyeth Pharmaceuticals, 2006-2007, \$116,485, Co-Investigator with Laurel Preheim, MD (PI), Martha Nielsen, PhD

VAPOR: Ventilator associated pneumonia outcomes research. Merck, Inc. 2004-2009, \$255,000, Principal Investigator

Comparison of lansoprazole solutab to intravenous lansoprazole. TAP, 2005-2008, \$106,000, Co-PI with John Devlin, Pharm.D. Northeastern College of Pharmacy, Boston, MA

Comparison of ciprofloxacin and moxifloxacin on QTc interval in critically ill patients. UNMC Research Support Fund. 2003 – \$33,000, Principal Investigator Keith Olsen, Co-investigators Pathak R, Nissen S, Fuller P

Drotrecogin alfa and the Treatment of Sepsis, A Pharmacotherapy Supplement. Eli Lilly Inc., \$100,000, 2002-2003, Principal Investigators: Brad Boucher, Keith Olsen, Rick Schiefe, Charles Carter

A comparison of omeprazole sodium bicarbonate immediate-release powder for suspension to intravenous cimetidine for the prevention of upper gastrointestinal bleeding due to stress related mucosal damage. SANTARUS, Inc. 2002-2003, \$12,500, Principal Investigator: Keith Olsen, Co-investigator: John DiBiase, Patrick Fuller

TIFPI: Randomized double-blind placebo controlled multicenter trial of tissue pathway factor inhibitor in severe sepsis. Chiron, Inc. 2001, \$20,000, Principal Investigator: Mark Rupp, Coinvestigator: Keith Olsen

Antimicrobial Activity of MK 826, Imipenem, Ceftriaxone, Cefepime, Piperacillin/Tazobactam Against TEM-10, TEM-26, and SHV-5 Derived Extended-Spectrum Beta-Lactamases Expressed in an Isogenic Escherichia coli Model, Merck, Inc. 2001-2002, \$35,750, Principal Investigator: Keith Olsen, Co-Investigators: Mark Rupp, Paul Fey

A comparison of the ARROWg+ard II Antimicrobial Surface Treated, Triple-lumen, Central Venous Catheters vs. Standard-Triple Lumen Catheters in a Randomized, Double-Blinded, Multicenter, Clinical Trial, ARROW International, 2000-2002, \$120,000, Principal Investigator: Mark Rupp, Co-investigator: Keith Olsen, Joseph Sisson

National Survey of Aspiration Pneumonia in the Intensive Care Unit: Focus on Antimicrobial Therapy, Roche Pharmaceuticals, 2000-2001, \$14,627.00, Principal investigator: Keith Olsen, Co-Investigator: Jill Rebuck

National Nosocomial Resistance Surveillance Group: A Multicenter, Cross-sectional Study of the Prevalence and Outcome of E. coli Infections with Reduced Ampicillin/Susceptibility, National Nosocomial Resistance Surveillance Group, 2000, \$2,775, Principal investigator: Keith Olsen.

In Vitro Testing of Antimicrobial Agents Against ESBL Producing Gram- Negative Bacteria in an Isogenic *E. coli* Model. Merck Laboratories, 1999, \$2,500, Principal investigator: Keith Olsen

In Vitro Testing of Antimicrobial Agents Against ESBL Producing Gram- Negative Bacteria in an Isogenic *E. coli* Model. Roche Laboratories, 1999, \$3,400, Principal investigator: Keith Olsen

Pharmacokinetics of Trovafloxacin in Adult Critically Ill Patients. Pfizer Pharmaceuticals, Inc. 1999, \$21,000, Principal investigator: Keith Olsen, Co-Investigators: Doug Fish, Jill Rebuck

Bench Mark Cost and Economic Study of Drug Induced Thrombocytopenia in the ICU. Source: Pharmacia & Upjohn, 1999, \$16,500, Principal investigator: Keith Olsen, Co-Investigator: Jill Rebuck

Comparison of Ciprofloxacin and Liposomal Ciprofloxacin G for the Treatment of Pneumococcal Pneumonia in a Cirrhotic Rat Model. Sequest, 1998, \$42,000, Principal Investigator: Laurel Preheim, Co-investigators: Keith Olsen, Martha Gentry

Open-Label, Randomized, Multicenter Phase III Study of Intravenous Synercid versus Vancomycin in the Treatment of Catheter -Related Infection. Rhone-Poulenc Rorer, Inc., 1998, \$3,500, Principal Investigator: Mark Rupp, Co-investigator: Keith Olsen

Linezolid in the Treatment of Gram-Positive Bacteremia. Pharmacia & Upjohn, 1998, \$8,000, Principal Investigator: Mark Rupp, Co-investigator: Keith Olsen

In vitro Comparison of Clarithromycin plus 14-Hydroxy-Clarithromycin and Azithromycin against Clinical Isolates of *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*. Abbott Pharmaceuticals, Inc., 1997, \$27,000, Principal investigators: Keith Olsen, Mark Rupp

A Multicenter Evaluation of the Safety and Efficacy of Voriconazole in Invasive Aspergillosis. Source: Pfizer Pharmaceuticals, Inc., 1997, \$7,500, Principal Investigator: Eduardo Dominguez, Co-investigator: Keith Olsen

Comparison of Trovafloxacin and Penicillin G for the Treatment of Pneumococcal Pneumonia in a Cirrhotic Rat Model. Pfizer, 1997, \$42,500, Principal Investigator: Laurel Preheim, Coinvestigator: Keith Olsen, Martha Gentry

Comparison of Parenteral Azithromycin and Penicillin G for the Treatment of Pneumococcal Pneumonia in a Cirrhotic Rat Model. Pfizer Pharmaceuticals, 1996, \$42,300, Principal investigator: Keith Olsen, Co-Investigators: Laurel Preheim, Martha Gentry

Impact of Formulary Management Systems on Product Utilization. Pfizer Pharmaceuticals, Inc., 1996-1997, \$80,000, Principal investigator: Keith Olsen.

TOPS: Nosocomial Pneumonia Surveillance Study. Source: Patient Outcomes Research Center, 1996, \$11,000, Principal investigator: Keith Olsen

American Society of Health-System Pharmacists Foundation Fellowship in Immunology. Project Title: The effect of immunological modulators on the in vitro antibiotic penetration across endothelial-epithelial cell layers. 1996, \$27,100, Principal Investigator: Keith Olsen, Fellow: Thomas Peddicord

Phase III Randomized, Open-Label, Multicenter Study of Synercid (Quinupristin/Dalfopristin) plus Aztreonam vs. Vancomycin plus Aztreonam in the Treatment of Gram-Positive Nosocomial Pneumonia. Rhone-Poulenc Rorer, Inc., 1996, \$25,000, Principal Investigator: Mark Rupp, Co-Investigator: Keith Olsen

Pharmacokinetics of Synercid in patients with Gram-Positive Pneumonia. Rhone-Poulenc Rorer, Inc. \$6,500, 1996, Principal Investigator: Mark Rupp, Co-Investigator: Keith Olsen

Randomized Placebo-Controlled Trial of MAK 195F in Sepsis with Hyper-inflammatory Response, Knoll Pharmaceuticals, 1996, \$123,500, Principal Investigators: Mark Rupp, Keith Olsen

A Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of TLC C-53 in Patients with Acute Respiratory Distress Syndrome (Protocol # C95-D-03). Source: The Liposome Company, 1996, \$15,000, Principal Investigators: Joseph Sisson, Keith Olsen

Surveillance of Resistant Gram-positive Bacteremia in the U.S. Clinical Pharmacokinetics Laboratory, Buffalo, NY, 1996, \$4,000, Principal Investigator: Keith Olsen

Comparison of Simple Omeprazole Solution to Ranitidine Continuous Infusion in Stress Ulcer Prophylaxis. Source: Patient Outcomes Research Center, 1995, \$10,000, Principal investigator: Keith Olsen

A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Flumazenil When Used To Reverse Sedation Induced by Benzodiazepines in Mechanically Ventilated Patients in the Intensive Care Unit. Hoffman La-Roche, 1994, \$30,000, Principal Investigators: Scott Buchalter, Keith Olsen

A Phase III Open Label, Non-Comparative Study of Amphotericin B Lipid Complex (ABLCL) in the Treatment of Definite or Probable Invasive Aspergillosis. Liposome, Inc. 1994, \$22,000, Principal Investigator: Ed Dominguez, Co-Investigator: Keith Olsen

A Phase III Study of r-methHuG-CSF in the Treatment of Severe Community Acquired Pneumonia. AMGEN, Inc. 1993, \$96,000, Principal Investigators: Gerardo San Pedro, Keith Olsen

CHES Trial. Centocor HA1A Evaluation in Septic Shock Trial. Centocor, Inc. 1992, \$24,000, Principal Investigators: John Cone, Gerardo San Pedro, Keith Olsen

Estimation of Azithromycin Concentrations in Serum Bronchoalveolar Lavage Fluid and Alveolar Macrophages after Multiple Doses in Normal Volunteers and Patients with Pulmonary Infections. Pfizer Central Research, 1992-1994, \$97,000, Principal Investigator: Keith Olsen, Co-Investigators: G. Douglas Campbell, Gerardo San Pedro

Open-Label Comparative, Safety, Tolerance and Efficacy Study of Parenteral Piperacillin/Tazobactam (CL298, 741) Versus Ceftazidime with Tobramycin for the Treatment of Patients with Hospital-Acquired Lower-Respiratory Tract Infections. Lederle, Inc. 1991, \$30,956, Principal Investigators: Gerardo San Pedro, Keith Olsen

Open-Label Comparative, Safety, Tolerance and Efficacy Study of Parenteral Piperacillin/Tazobactam (CL298, 741) with Tobramycin versus Imipenem/Cilastatin with Tobramycin for the Treatment of Hospitalized Patients with Septicemia. Lederle, Inc., 1991, \$35,592, Principal Investigators: Gerardo San Pedro, Keith Olsen

Development of a Tyramine Analysis Center. Source: UAMS Foundation Fund for Medical Research, 1990 \$3,710, Principal Investigator: Michael S. Monaghan, Co-Investigator: Keith Olsen

Effect of Glycosylated Albumin on Phenytoin Binding In Elderly NIDDM. Source: Upjohn Pharmacy Liaison, 1989, \$580, Principal Investigator: Keith Olsen, Co-Investigator: Barbara Kostic

Evaluation of Clonidine during the perioperative period. Source: Boehringer Ingelheim, Pharmaceutical Inc., 1989, \$7,434, Principal investigator: William Golden, Co-Investigator: Keith Olsen

Effect of Single Dose Famotidine, Cimetidine, and Ranitidine in Neutralizing Gastric Acid in Critically Ill Patients: A Randomized, Double Blind, Cross-over Trial. Merck Research, 1989, \$10,000, Principal Investigator: Keith Olsen, Co-Investigator: Charles Hiller

Double-Blind, Randomized Placebo Controlled Group of Safety and Efficacy of Xomen-E5. Source: Xoma Corporation, 1989, \$25,000, Principal investigator G. Douglas Campbell, Co-Investigator: Keith Olsen

Double-Blind, Randomized Placebo Controlled Group Comparative Study of the Safety and Efficacy of Xomen-E5. Xoma Corporation, 1989, \$32,100, Principal investigators: Keith Olsen, Gerardo San Pedro

Use of Nuclear Magnetic Resonance Spectroscopy and Imaging to Detect Trifluoroethyl Penicillin V in Rat Bladder. Source: Eli Lilly, 1989, \$15,000, Principal investigator: G. Douglas Campbell, Co-Investigator: Keith Olsen

A Randomized Trial of Ceftizoxime vs. Cefoxitin in the Therapy of Lower Extremity Infections in Diabetic Patients. Source: Smith-Kline-French, Pharmaceuticals Inc., 1988, \$38,171, Principal Investigator J.B. Cone, Co-Investigator: Keith Olsen, Bruce Ackerman

A Comparison of Ampicillin plus Sulbactam versus Cefoxitin in the Treatment of Intra-Abdominal Infections of Bacterial Etiology. Source: Roerig Pharmaceutical Inc., 1988. \$96,480, Principal Investigator: R.W. Bradsher, Co-Investigator: Keith Olsen, Bruce Ackerman

A Randomized Blinded Comparative Study of Teicoplanin versus Vancomycin in the Treatment of Vascular-Access Associated Bacteremia/Septicemia Caused by Gram-Positive Bacteria. Source: Merrell Dow Research Institute, 1988, \$15,000, Principal Investigators: R.W. Bradsher, Keith Olsen, Co-Investigator: Bruce Ackerman

Effect of Cimetidine Infusion on Lymphocyte Number and Function. Source: Smith, Kline, French, Inc., 1987, \$10,000, Principal Investigator: B.H. Ackerman, Co-Investigator: Keith Olsen, J.B. Cone

Electrophysiologic Study of Oral Quinidine. Source: American Heart Association, 1987, \$19,368, Principal Investigator: E.L. Kennedy, Keith Olsen, Bruce Ackerman

Reversal of Central Benzodiazepines Effects by Intravenous Flumazenil (RO15-1788) After Conscious Sedation Produced by Valium. Source: Hoffman-LaRoche, Inc., 1987, \$33,000, Principal Investigators: Keith Olsen, Carmelita Pablo

Reversal of Central Effects of Versed^R (Midazolam) by Intravenous Flumazenil (RO 15-1788) or Placebo After General Anesthesia in Patients Pre-medicated with Fentanyl of Sufentanil. Source: Hoffman LaRoche, Inc., 1987, \$33,000, Principal Investigators: Keith Olsen, Carmelita Pablo

Theophylline Pharmacokinetics in Burn Patients. University of Arkansas for Medical Sciences Faculty Grant, 1986, \$2,500, Principal investigator: Keith Olsen, Co-Investigators: J.B. Cone, Greg Kearns

Electrophysiologic Study of Free and Total Quinidine. Source: University of Arkansas for Medical Sciences Pilot Study Grant, 1986, \$5,000, Principal investigator: E.L. Kennedy, Co-investigator: Keith Olsen

Heparin Pharmacokinetics in Multisystem Organ Failure. Source: Roche Laboratories, Division of Hoffman-LaRoche, Inc. (Hospital Pharmacy Research Grant Award), 1986, \$3,500, Principal Investigator: Keith Olsen, Co-Investigator: J.B. Cone

CONSULTING/ADVISORY BOARDS

Wright Medical Technology - Memphis, Tennessee
Pfizer Pharmaceuticals, Inc., New York, New York
Astra/Zeneca, West Point, Pennsylvania
Merck, Inc., West Point, Pennsylvania
Roche Laboratories, Nutley, New Jersey
Bristol-Myers Squibb, Princeton, New Jersey
Abbott Pharmaceuticals, Abbott Park, Illinois
TAP, Chicago, IL
Lilly Critical Care, Indianapolis, Indiana
SANTARUS Pharmaceuticals, San Diego, CA
Wyeth, Blue Bell, Pennsylvania
Ortho-McNeil, Raritan, NJ
MEDSCAPE Drug Reference Advisory Board – 2010 to 2015
RxResults Board of Directors, 2016-2019

EDITORIAL BOARD

The Annals of Pharmacotherapy, Section on Pulmonary and Allergy 1991-1997
Mosby's Drug Consult – 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2012, 2013, 2014
World Journal of Gastrointestinal Pharmacology & Therapeutics – 2009-2018

HONORS

Lambda Delta Lambda (National Science Honorary) (1975)
Blue Key (Men's Honorary Society) (1976)
Cum Laude graduate (1977)
Student Senate - University of Nebraska Medical Center (1979-80)
Rho Chi Pharmaceutical Honor Society (1981)
Who's Who in the South and Southwest (1988)
Teacher of the Year (1991-92 academic year)
Merck Pharmacy Achievement Award (1993)
Outstanding Clinical Faculty Award (U. Arkansas) (1993)
Fellow, American College of Clinical Pharmacy (1995) ASHP Immunology
Fellowship Preceptor (1996-1997)
Distinguished Teaching Award, University of Nebraska Medical Center, College
of Pharmacy [1998, 2005 (first repeat award recipient)]
Alvin M. Earle Outstanding Health Science Educator, University of Nebraska
Medical Center Student Senate, Nominee, (1999)
Society of Critical Care Medicine (SCCM) Health Care Industry Specialty Award
(for research: Thrombocytopenia-Associated Costs in an Adult Intensive
Care Unit Population)
Resident Preceptor of the Year – UNMC/NHS Department of Pharmaceutical
Services 1996, 2001
Vice-Chair, Commission on Therapeutics, ASHP 2002
Chair, Commission on Therapeutics, ASHP, 2003-04
Fellow, American College of Critical Care Medicine (FCCM), January 2003
SCCM Clinical Pharmacy and Pharmacology Advisory Board (elected) 2004-
2006
SCCM, Presidential Citation, 2004
SCCM, Presidential Citation, 2007
SCCM, Presidential Citation, 2008
SCCM, Presidential Citation, 2020
SCCM, Presidential Citation, 2021
ACCP, Chair Best Poster Award spring 2005
Lead, Professor Walk Rounds, 35th, 36th, 37th, 40th Annual Meeting of the
Society of Critical Care Medicine, January, 2006, 2007, 2008, San
Francisco, CA, Orlando, CA, Honolulu, HI, San Diego, CA.
Pharmacist: 2008, 2012 U.S. Olympic Swim Trials
Elected Board of Regents, American College of Critical Care Medicine 2010-
2013 Re-elected 2013-2016
Elected, Trustee, American College of Clinical Pharmacy Research Institute
2012-2014

American College of Clinical Pharmacy, Critical Care PRN Career Research Award 2016

Alumni of the Year, Health Sciences Division, Wayne State College, 2016

Drug Therapy Research Award, ASHP Foundation, American Society of Health-Systems Pharmacists 2016

Elected Secretary General, American College of Critical Care Medicine 2016-2017

Elected Vice-Chancellor, American College of Critical Care Medicine 2017-2018

SCCM Star Research Achievement Award – 2018 SCCM Congress

Elected Chancellor, American College of Critical Care Medicine, 2018-2019

Immediate-past Chancellor, American College of Critical Care Medicine, 2019-2020

Dean's Endowed Chair, College of Pharmacy, University of Arkansas for Medical Sciences, 2015-2019

Elected, Board of Regents, American College of Clinical Pharmacy 2021-2024

PROFESSIONAL SOCIETY MEMBERSHIPS/SERVICE

American College of Clinical Pharmacy (1985-present)

American Society of Health-System Pharmacists (1977-present)

Arkansas Association of Hospital Pharmacists (1985-1993, 2015-present)

Arkansas Pharmacy Association (1985-1993, 2015-present)

American Association of Colleges of Pharmacy (1981-present)

American College of Clinical Pharmacology (1990-2000)

American Society of Microbiology (1992-present)

American Society of Parenteral and Enteral Nutrition (1987-1988)

Kappa Psi (Pharmaceutical Fraternity) 1978

Mid-south Chapter of American College of Clinical Pharmacy (1990-1993)

Rho Chi (1985-present)

Society of Critical Care Medicine (1992-present)

Committees:

National

Faculty Delegate American Association of Colleges of Pharmacy 1988

ASHP Program Advisor 1989

ASHP Network for Student's 1986-present

Education Committee (ACCP) 1993, 1994, 1995

UHC Biotechnology Monitor 1992-1998

Program Coordinator (ASHP) 1989

UHC Critical Care Pharmacoeconomics 1994-1998

Industrial Relations Committee (ACCP) 1995-1997

ASHP expert panel member (Stress

Related Mucosal Damage)	1997-1998
Critical Care Practice & Research Network Newsletter, Editorial Staff	1996-1997
ACCP Critical Care PRN Newsletter Editorial Staff	1996-1998
ACCP Membership Committee Regional Recruiter	1996-1998
ACCP Membership Committee National Committee	1997-1998
Chair Critical Care PRN Research Research Committee – ACCP	1997-1998
Judge, 23rd Annual Midwest Pharmacy Residents Conference	1996, 1997
APhA Peer Reviewer for APhA Guide to Drug Treatment Protocols: Respiratory and Allergic Diseases	1998
APhA Panel Member for APhA Guide to Drug Treatment Protocols: Gastrointestinal Diseases	1998
Judge, Midwest Student Biomedical Research Forum	1998, 1999
ASHP Section of Clinical Specialists Nominations Committee	1999, 2000
ASHP Foundation Literature Awards Program Selection Panel	2000, 2001, 2003, 2006, 2008
ASHP Critical Care Section Chair	1999-2000
ASHP Commission on Therapeutics	2000-2004
Surgical Infection Prevention (SIP)	2000-2003
Surgical Care Intervention Project	2003-2015
SCCM Fellowship Grant Review SCCM/ CPP section Research Committee (chair)	2000, 2001 2001-2002
SCCM Research Committee	2002-2004
SCCM/ CPP section task force on Clinical Pharmacist Manpower and Services (Co-chair)	2002-2003
SCCM Ethics Committee	2003
ACCM Credentials Committee	2003-2005
SCCM Job Description/Contracts Publication (Chair)	2003-2004
SCCM “White Paper” on ICU Research	2004-2008
SCCM “Critical Care as a Specialty”	2004-2007

ACCP, Best Poster Judge & Chair (Spring mtg.)	2005
ACCM Credentials Committee (vice chair)	2005-2006
ACCM Credentials Committee (chair)	2006-2008
Critical Care PRN (ACCP) Research Travel Award	2006-2010
ASHP Research and Education Foundation – Judge Research	2005
ACCP Resident-Fellow Award Committee Critical Care PRN	2005-2009
National Quality Forum (NQF). National Consensus Standards for Reporting of Health-Care Associate Infection Data. Technical Advisory Panel on Surgical Site Infections. 2006-2007	
Co-Chair Joint Task Force for “Antimicrobial Surgery Prophylaxis” development of a national guideline with the Infectious Diseases Society of America, Surgical Infection Society and American Society of Health-System Pharmacists, 2006- 2012, 2020-	
Critical Care Research Task Force	2007-2010
Judge, Midwest Residency Research	2008, 2009
ACCP Program Committee	2008-2010
American College of Critical Care Medicine Board of Regents (elected)	2009-2020
AACP Faculty Workforce Taskforce	2009-2010
Fellowship Services Committee (ACCM) (co-chair)	2010-2012
Guidelines Management (ACCM) (chair)	2011-2014
Simulation Task Force (SCCM)	2011-2015
AACP Scholarship/Research Develop.	2011-2012
AACP New Investigator Award I reviewer	2012
SCCM Simulation Task Force	2012-2015
AACP Task Force on Research Funding	2012-2013
SCCM Research Summit Committee	2013-2016
Critical Care Pharmacy Trials Network Board of Directors	2011-2017
CMS Hospital eMeasures Technical Expert Panel	2012-2014
AACP Research Committee	2012-2014
ACCP Awards Committee	2013-2014
NQF Surgery Measures	2014-2020
SCCM Program Committee	2015-2019, 2020-2023

AACP PCAT Advisory Committee	2016-2019
Discovery (SCCM) Critical Care Research Network Steering Committee	2017-2020

State

Programs Committee	1986-1990
Arkansas Association of Hospital Pharmacists	
ACCP Local Chapter Development Committee	2003-2007
NPA Smoking Cessation Task Force	2008-2009
NCCPE (Nebraska Committee on Continuing Pharmacy Education	2009-2012
NPA Program Committee	2013-2014
Arkansas Tripartite Committee on Continuing Pharmacy Education	2015-2019
Arkansas Pharmacy Association Board of Directors	2015-2019
Arkansas Association of Health System Pharmacists Board of Directors	2016-2019
Nebraska Pharmacy Association Board of Directors	2021-

EDITORIAL AND REVIEW ACTIVITIES

Journal Referee:

American Journal of Health-System Pharmacists, 1981 to present
Pharmacy Times, 1985 to 1994
Annals of Pharmacotherapy, 1986 to present
Pharmacotherapy, 1990 to present
Mosby Publishing, Inc., 1986 to present
Springhouse Incorporation, 1986 to present
Heart & Lung: The Journal of Critical Care, 1992 to present
APhA - Disease-Specific Pharmaceutical Care Protocols, 1995-1998, 2000
 Gastrointestinal and Pulmonary Diseases
American Journal of Gastroenterology, 1997
Antimicrobial Agents and Chemotherapy, 1996 to present
Journal of the American Pharmaceutical Association, 1998
adis International - 2009
Critical Care Medicine – 1999 to present
Journal of Antimicrobial Chemotherapy – 2000 to present
Clinical Infectious Diseases – 2000 to present

Advisory Board, Mosby's Drug Consult for Nurses - 2005
Medical Letter - 2004
Grant Review Committee: ASHP 2009
Hospital Pharmacist-Emergency Physician Collaborative 2009
Journal of Gastrointestinal and Liver Diseases – 2009
Nursing Spectrum Drug Handbook – 2009
JAMA – 2010
Journal of Clinical Medicine and Research – 2010
Surgical Infections – 2010
Drugs – 2010
Nurses Drug Handbook 2012- Lippincott – contributor
Nurses Drug Handbook, 6th edition, McGraw-Hill, 2012 – contributor
Respiratory Care – reviewer - 2011
ACCP Pharmacotherapy Prep Course – reviewer – 2011-2012

Poster/Abstract Reviewer

American Society of Health-System Pharmacists Midyear Clinical Meeting,
1983 to 2015
American College of Clinical Pharmacy, 1993 to present
Society of Critical Care Medicine 1998 to present
American Association of Colleges of Pharmacy 2009 to 2016

Grant Reviewer

ACCP Research Institute - Pulmonary Research Award Selection Panel, 1992
ASHP Foundation Awards Program Selection Panel (1991, 1994, 1998, 1999,
2003, 2006, 2007, 2009)
Astra Clinical Pharmacy Research Award (2001, 2002)
ACCP Research Institute - Critical Care Fellowship Selection Panel, 1998
SCCM CPP Section Grant/Fellowship Reviewer – 2000, 2001, 2002, 2003
SCCM Patient Safety Grant Reviewer – 2002, 2003
ACCP Research Institute Junior Investigator 2017, 2018, 2019, 2020

COMMITTEE ACTIVITIES

Nebraska:

College Committees

Admissions	1994-2015
Recruitment	1994-1997
Course Coordinators	1996
Grade Appeals	1997
Pharmacy Practice Chair Search	1997
Chair, Pharmacy Practice Faculty Srch.	1997-1999
Clerkship Committee	1997-1998

Promotion and Tenure	1999-2007
Promotion and Tenure, Chair	2004-2005, 2005-2006
Curriculum	1999-2001
Academic Performance	2000-2002, 2004, 2005
Clerkship and Preceptor Evaluation	2002-2002
Faculty Mentoring	2002-2003
Strategic Planning Committee	2003-2009
Faculty Development Committee	2003-2005
Scholarships, Honors and Financial Aid	2005-2010
ACPE Self-Study Subcommittee	2006
Mission, Planning, and Assessment	
Accreditation Steering	2007
Dean's Search	2007
Executive Committee – COP	2007-2015
UNMC Continuing Education	2008-2015
Accreditation Steering and ACPE	2012
Subcommittee Chair	
Executive Leadership, Chair	2019-

Hospital/University

Critical Care	1994-1998
Chancellor's Clinical Research Center	1995
Feasibility Team	
Clinical Research Center	1995-1996
Implementation Team	
Seed Grant Review Committee	
Clinical Section	1996-1998
Clinical Research Advisory Team	1996-2010
Nosocomial Outcomes Research Team	1996-1999
Investigational Review Board (IRB)	2002-2015
Residency Board of Directors	2007-2015
Area Health and Education	2007-2015
Continuing Education	2008-2015
UNemed Advocate Advisory Board	2008-2015
Continuing Education Committee	2010-2015
College of Medicine	
Patient Oriented Research Council	2010-2015
Primary Care Center Steering Committee	2012-2015
Urban Health Advisory Council	2014
NCAT (campus accreditation)	2014
Chancellor's Cabinet	2019-
Council of Dean's	2019-

Cancer Center Director Search Committee 2019
iExcell Advisory Board 2019-
Global Center for Health Security Leadership 2020-

Arkansas

College Committees

Admissions 1987-1993
Curriculum 1991-1993
Non-traditional Pharm.D. Advisory 1990-1993
Grants and Contracts 1990
Physical Facilities (Accreditation) 1992
Professional Practice Plan 1987
RxResults Board of Directors 2016-2019
Executive Team Leader 2015-2019

Bio-ventures Board of Directors 2015-2019
Communications 2016-2019
COBRE Internal Advisory 2016-2019

University Committees

Investigational Review Board (IRB) 1989-1993
Future Now 1990
Chancellors Cabinet 2015-2019
Council of Deans 2015-2019
COPH Dean Search 2018-2019
Enterprise Risk Management (Academic chair) 2018-2019

Hospital Committees

Pharmacy Residency 1989-1993
Nutrition Support 1986-1991
Critical Care 1990-1993
Drug Review Subcommittee(s) 1986-1993

GRADUATE PROGRAM EXPERIENCE

Director, Critical Care/Infectious Diseases Pharmacotherapy
Research Post-Doctoral Fellowship (4 trained)
Department of Pharmacy Practice, University of Nebraska
Medical Center, Omaha, Nebraska

Primary Preceptor: Adam Pitz, Ph.D., Post-doctoral fellow,
2009-2010 Position: Microbiologist, Proctor and Gamble, Cincinnati, OH

Primary Preceptor: Jill A. Rebuck, Pharm.D, (1998- 2000)
Position: Clinical Specialist, Department of Pharmaceutical
Services and Adjunct Associate Professor, Department of
Surgery, University of Vermont Medical Center, Burlington, VT

Primary Preceptor: Kimberly L. Bergman, Pharm.D. (1997-1999)
Position: Food and Drug Administration (FDA), Drug Pharmacodynamics
Division, Rockville, MD

Primary Preceptor: Thomas E. Peddicord, Pharm.D. (1995-1997) Position:
Senior Clinical Liaison, Aventis Pharmaceuticals, Inc., Nutley, NJ

BIBLIOGRAPHY (H-index 31)

ORIGINAL CONTRIBUTIONS

1. **Olsen KM**, Thompson DT, Sullivan M. Possible Agranulocytosis Secondary to Zomepirac. Clin Pharm 1984;3:85-87.
2. **Olsen KM**, Chatska S. Drug Use in Sports. Oklahoma Pharmacist 1984;10:4-13.
3. **Olsen KM**, DuBe' JE. Evaluation of Two Methods of Patient Education. Am J Hosp Pharm 1985; 42:622-624.
4. **Olsen KM**, Barton CI. Peptic Ulcer Disease. Pharm Times 1986; 1:108-112.
5. Barton CI, **Olsen KM**. The Role of the Pharmacist and Case Studies in Diabetes Mellitus. Therapeutic Management of Diabetes Mellitus. ed. Malone MH, Pharmat Inc., Lawrence, Kansas 1986, pp.81-112.
6. **Olsen KM**, Coniglione TC, Barton CI. Response of Platelets to Intravenous Iron Dextran in Reactive Thrombocytosis. Clin Pharm 1987;6:417-420.
7. **Olsen KM**, Hiller FC. Tetanus: Report of Two Cases and Review of the Literature. Clin Pharm 1987; 6:570-574.
8. **Olsen KM**, Barton CI. Peptic Ulcer Disease. J Pract Nurs 1987; 37(4):20-27.

9. Ackerman BH, Taylor EH, **Olsen KM**, Abdul-Malak W, Pappas AA. Vancomycin Serum Protein Binding Determination by Ultrafiltration. *Drug Intel Clin Pharm* 1988; 22(4):300-303.
10. Yu-Hsing T, Stiles ML, Allen LV, **Olsen KM**. Stability of Amoxicillin trihydrate-potassium clavulanate in original containers and unit dose oral syringes. *Am J Hosp Pharm* 1988; 45:1092-1099.
11. Chen BH, Taylor EH, Kennedy E, Ackerman B, **Olsen KM**. Total and Free Quinidine by Fluorescence Polarization Immunoassay and Comparison with High Performance Liquid Chromatography. *Clinica Chimica Acta* 1988; 175:107-108.
12. Bradsher RW, Ackerman BH, **Olsen KM**, Martin RE. Antibacterial agents for critically ill patients. Part I. *J Crit Illness* 1988; 3(11):47-57.
13. Bradsher RW, Ackerman BH, **Olsen KM**, Martin RE. Antibacterial agents for critically ill patients. Part II. *J Crit Illness* 1988; 3(12):19-26.
14. **Olsen KM**, Hiller FC, Ackerman BH, McCabe BJ. Effect of Enteral Tube Feedings on Phenytoin Absorption. *Nutr Clin Pract* 1989; 4:176-178.
15. Ackerman BH, **Olsen KM**, Kennedy EE et al. Disposition of 3-Hydroxyquinidine in Patients Receiving Initial Intravenous Quinidine Gluconate for Electrophysiology Testing of Ventricular Tachycardia. *Ann Pharmacotherapy* 1989;23:375-378.
16. Ackerman BH, **Olsen KM**, Kennedy EE, Taylor EH, Chen BH, Jordan D, Ackerman DJ. Disposition of Dihydroquinidine in Seven Patients Receiving Intravenous Quinidine Gluconate for Electrophysiologic Testing of Ventricular Tachycardia. *Pharmacotherapy* 1989; 9(4):220-225.
17. Kostic BAP, **Olsen KM**, Kearns GL, Kemp SF. Effect of Glycosylated Albumin on Phenytoin Protein Binding in Elderly Type II Diabetics. *Pharmacotherapy* 1990;10(5):362-365.
18. **Olsen KM**, Pablo C, Ackerman BH. Postoperative Analgesic Requirements Following Intravenous Flumazenil (RO 15-1788). *Ann Pharmacother* 1990; 24:1159-1163.
19. Ackerman BH, **Olsen KM**, Pappas AA. Isopropanol Ingestion: A Report of Six Episodes with Isopropanol and Acetone Serum Concentration-Time Data. *J Toxicol: Clin Toxicol* 1991; 29(1):11-21.

20. **Olsen KM**, Campbell GD. E5 Monoclonal IgM Antibody for the Treatment of Gram-Negative Sepsis. *Ann Pharmacother* 1991; 25:784-790.
21. Greenman RL, Schein RMH, Martin MA et al. and the Xoma Sepsis Study Group (includes **Olsen KM**). A Controlled Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis. *JAMA* 1991; 266:1097-1102.
22. Goad DL, Davis CM, Liem P, **Olsen KM**. The Use of Selegiline (L-deprenyl) in Alzheimer's Patients with Behavior Problems. *J Clin Psych* 1991;52:342-345.
23. Herrmann D, **Olsen KM**, Hiller FC. Nicotine Absorption Following Pulmonary Instillation. *J Pharm Sci* 1992;81(11):1055-58.
24. Campbell GD, Ramaprashad S, **Olsen KM**, Komoroski R, Tryka F, Blaszcak L, Parr TR. Fluorine Nuclear Magnetic Resonance Spectroscopy and Imaging of Antibiotics in Rats. *J Pharm Sci* 1993; 82:48-41.
25. **Olsen KM**, Ma F, Edrington D, Stull RE, Ackerman BH. Effect of Intestinal Lavage on Salicylate Absorption: A Comparison against Standard Means of Gastrointestinal Decontamination. *Pharmacotherapy* 1993;13(3):229-232.
26. Burch S, Gann LP, Erbland M, **Olsen KM**. Effect of pH on Nicotine Absorption. *J Aerosol Med* 1993;6(1):45-52.
27. Monaghan MS, Falls L, **Olsen KM**. Potential Drug Interactions with H2-Receptor Antagonists in Intensive Care Unit Patients. *Hosp Pharmacy* 1993;28:300-305.
28. Monaghan MS, Ackerman BH, **Olsen KM**, Farmer C, Pappas AA. Use of Delta Osmolality to Predict Serum Isopropanol and Acetone Concentrations. *Pharmacotherapy* 1993; 13:60-63.
29. **Olsen KM**, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of Flumazenil in the Presence of Medications Given by Continuous Infusion. *Am J Hosp Pharm* 1993; 50:1907-1912.
30. Cone JB, Wallace BH, **Olsen KM**, Caldwell FT, Gurley BJ, Bone PJ. Burn Injury Alters the Pharmacokinetics of Enteral Ibuprofen. *J Burn Care Rehab* 1993; 14:666-669.

31. Hiller FC, **Olsen KM**, Gann LP, Erbland ML. Nicotine Blood Levels Measured After Smoking Cigarettes Designed to Release Nicotine by Heat Evaporation (Instead of Burning). *S.T.P. Pharma Sciences* 1994; 4(1):77-81.
32. Monaghan MS, Glasco G, St.John G, **Olsen KM**. Safe Administration of Iron Dextran to a Patient who Reacted to the Test Dose: A Case Report. *S Med J* 1994; 87(10):10101012.
33. Davis GA, **Olsen KM**. Pharmacokinetic Services in Arkansas Hospitals. *Arkansas Pharmacists* 1994; 67:22-23.
34. **Olsen KM**, Marx MA, Monaghan MS, Barnes E, Ackerman BA, Pappas AA. Phenytoin and Plasmapheresis. Importance of Sampling Times and Impact of Obesity. *Ther Drug Monit* 1994; 16:624-628.
35. Monaghan MS, **Olsen KM**, Ackerman BH, Fuller GL, Porter WH, Pappas AA. Measurement of Isopropanol and the Acetone Metabolite by Proton Nuclear Magnetic Resonance: Application to the Detection of Pharmacokinetic Parameters in a Simulated Overdose Model. *Clin Toxicol* 1995;33(2):141-149.
36. **Olsen KM**, Gurley BJ, Davis GA, Ma FH, Archer S, Ackerman BH. Comparison of fluid volumes with whole bowel irrigation in a simulated overdose. *Ann Pharmacother* 1995; 29:246-250.
37. Gurley BJ, Marx MA, **Olsen KM**. Phenytoin Free Fraction Determination: Comparison of an Improved Direct Serum Injection High-Performance Liquid Chromatographic Method to Ultrafiltration Coupled with Fluorescence Polarization Immunoassay. *Journal of Chromatography B: Biomedical Applications* 1995; 670:358-364.
38. **Olsen KM**, Kearns GL, Kemp S. Glyburide Protein Binding and the Effect of Albumin Glycation in Pediatric and Elderly Patients with Diabetes. *Journal of Clinical Pharmacology* 1995; 35(7):739-745
39. **Olsen KM**, Hiller FC, Ackerman BH, Crisp-Landwehr K, San Pedro GS. Effect of Histamine-2 Receptor Antagonists as a Single Intravenous Dose on Gastric pH and Volume in Critically Ill Patients. *Current Therapeutic Research* 1995;56(8):756-768.
40. Bone RC, Balk RA, Fein AM et al. and the Xoma Sepsis Study Group (includes **Olsen KM**). A Second Large Controlled Clinical Study of E5, a Monoclonal

- Antibody to Endotoxin: Results of a Prospective, Multicenter, Randomized, Controlled Trial. *Critical Care Medicine* 1995; 23:994-1006.
41. **Olsen KM**, San Pedro GS, Gann LP, Gubbins PO, Halinski DM, Campbell GD. Intrapulmonary Pharmacokinetics of Azithromycin in Healthy Volunteers Given Five Oral Doses. *Antimicrobial Agents and Chemotherapy* 1996; 40:2582-2585.
 42. **Olsen KM**, Peddicord TE. Pharmacotherapy of Community-Acquired Pneumonia. *Hospital Pharmacy Times* 1996;9:5-17.
 43. Peddicord TE, **Olsen KM**, ZumBrunnen TL, Warner DJ, Webb L. Stability of Concentrated Dopamine Hydrochloride, Norepinephrine Bitrate, Epinephrine Hydrochloride, and Nitroglycerin in Dextrose 5% and Water. *American Journal of Health-System Pharmacy* 1997; 54:1417-1419.
 44. Peddicord TE, **Olsen KM**, Collier DS. Effect of Lansoprazole, Omeprazole, and Ranitidine on the DNA Synthesis of Mononuclear Cells. *Critical Care Medicine* 1999; 27(1):90-94.
 45. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. Erstad B, **Olsen KM**, Boucher B, Harrington A, et al. *American Journal of Health-System Pharmacists* 1999; 56:347-379.
 46. Preheim LC, **Olsen KM**, Yue M, Snitily MU, Gentry MJ. Efficacy and Pharmacokinetics of Azithromycin, Trovafloxacin, and Ceftriaxone in an Ethanol-Fed Rat Model of Pneumococcus Pneumonia. *Alcohol: Clinical Experimental Research* 1999; 23(5):842849.
 47. Bergman KL, **Olsen KM**, Peddicord TE, Fey PD, Rupp ME. Comparative Study of Bactericidal Activity and Post-antibiotic Effect (PAE) of Physiological Levels of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin against Clinical Isolates of *Haemophilus influenzae*. *Antimicrobial Agents and Chemotherapy* 1999; 43(5):12911293.
 48. Bergman KL, **Olsen KM**, Rupp ME. Relevance of pulmonary tissue concentrations of macrolide antibiotics. *Recent Research Developments in Antimicrobial Agents & Chemotherapy* 1999; 3:271-279.
 49. Preheim LC, Yu M, Snitily MU, **Olsen KM**. Comparison of Azithromycin, Trovafloxacin, and Ceftriaxone for Pneumococcal Pneumonia in Ethanol-Fed Rats. *New Considerations for Macrolides, Azalides, Streptogramins, and Ketolides. Proceedings from the ICMASK, 2000*; 4:649-652.

50. **Olsen KM**, Peddicord TE, Campbell GD, Jr, Rupp ME. Antimicrobial Effects of Lidocaine in Bronchial Washings and Bronchoalveolar Lavage. *Journal of Antimicrobial Chemotherapy* 2000; 45:217-219.
51. DiGiacinto JL, **Olsen KM**, Bergman KL, Hoie EB. Stability of Liquid Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Syringes. *Annals of Pharmacotherapy* 2000;34(5):600-605.
52. **Olsen KM**, Rebuck JA, Weidenbach T, Fish DN. Intravenous trovafloxacin pharmacokinetics in adult critically ill patients. *Pharmacotherapy* 2000; 20(4):400-404.
53. Rebuck JA, **Olsen KM**, Fey PM, Bergman KL, Rupp ME. *In Vitro* Activities of Parenteral Beta-Lactam Antimicrobials against TEM-10, TEM-26, and SHV-5 Derived Extended-Spectrum Beta-Lactamases by Time-Kill Curve Methods. *Journal of Antimicrobial Chemotherapy* 2000; 46:461-464.
54. Rebuck JA, **Olsen KM**, Fey PD, Langnas AN, Rupp ME. Characterization of an Outbreak Due to ESBL-Producing *K. pneumoniae* in a Pediatric Intensive Care Unit Solid Organ Transplant Population. *Clinical Infectious Diseases* 2000;31(6):1368-1372.
55. **Olsen KM**, Rebuck J, Rupp ME. Arthralgias and Myalgias Related to Quinupristin/Dalfopristin Administration. *Clinical Infectious Diseases* 2001; 32(15 February):e83-86.
56. Phillips JO, **Olsen KM**, Rebuck JA, Metzler MH. A Randomized, Pharmacokinetic and Pharmacodynamic, Cross-Over Study of Duodenal or Jejunal Administration Compared to Nasogastric Administration of Omeprazole Suspension in Patients at Risk for Stress Ulcers. *American Journal of Gastroenterology* 2001; 96:367-372.
57. **Olsen KM**, Bergman KL, Rebuck JA, et al. Pharmacokinetics and Pharmacodynamics of Omeprazole in Critically Ill Pediatric Liver/Intestinal Transplant Patients. *Pediatric Critical Care Medicine* 2001;2(3):232-237.
58. Monaghan MS, Marx MA, **Olsen KM**, et al. Correlation and Prediction of Phenytoin Protein Binding Using Standard Laboratory Parameters in Patients Following Renal Transplantation. *Therapeutic Drug Monitoring* 2001; 23(3):263-267.

59. Rebeck JA, Rasmussen JR, **Olsen KM**. Aspiration-related practice patterns in the intensive care unit: A physician survey. *Critical Care Medicine* 2001; 29:2239-2244.
60. Gentry MJ, **Olsen KM**, Preheim LC. The pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. *Antimicrobial Agents and Chemotherapy* 2002;46(5):1345-51.
61. Kaufman SS, Lyden ER, Brown CR, et al #6. Omeprazole Therapy in Pediatric Patients Following Liver and Intestinal Transplantation. *Pediatric Gastroenterology and Nutrition* 2002;34:194-198.
62. **Olsen KM**. Medication Errors: Problems Identified, What is the Solution? *Crit Care Med* 2002; 30:944-45.
63. McClaren AC, McClaren SG, **Olsen KM**, Nelson C. The effect of sampling methods on the elution of tobramycin from calcium sulfate beads. *Clinical Orthopaedic Related Research* 2002;403:54-57.
64. Nelson CL, McLaren SG, Skinner RA, et al #6: The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. *Journal of Orthopaedic Research* 2002; 20:643-47.
65. **Olsen KM**, Martin SJ. Clinical Pharmacokinetics and Use of Drotrecogin alfa (activated). *Pharmacotherapy* 2002;22(12 Pt2):196S-205S.
66. **Olsen KM**, Skiermont K, Campbell GD. Antibiotic Pharmacodynamics in Respiratory Tract Infections. *Journal of Respiratory Disease* 2002;23(11):561-568.
67. Boucher BA, **Olsen KM**. Drotrecogin alfa (activated) in Patients with Severe. *Pharmacotherapy* 2002;22(12 Pt2):167S-168S.
68. Ellbogen MH, **Olsen KM**, Preheim LC, Gentry MJ. Efficacy and pharmacodynamics of ciprofloxacin vs. liposomal ciprofloxacin in a pneumococcal rat model of pneumonia. *Journal of Antimicrobial Chemotherapy* 2003; 51:83-91.
69. Kane S, **Olsen KM**. How to write an abstract suitable for publication. *Hosp Pharm* 2004: 39:92-95.

70. Surgical Infection Prevention Guideline Writers Workgroup (includes **Olsen, KM**). Antimicrobial prophylaxis for surgery: An advisory statement from the national surgical infection prevention project. *Clinical Infectious Diseases* 2004;38:1706-1715
71. **Olsen KM**, Rudis MA, Rebuck JA, Belmont D, Mehdian R, Nelson C, Rupp ME. Effect of Single Daily Dose vs. Multiple Daily Dosing of Tobramycin on Alanine Aminopeptidase and N-acetyl- β -D-glucosaminidase Excretion. *Critical Care Medicine* 2004; 32:1678-1682.
72. **Olsen KM**, Szejman E, Fiel S. Pharmacotherapeutic Management of COPD in the Critical Care Setting. *Pharm Pract News* December, 2004;21-24.
73. Preheim LC, **Olsen KM**, Yue M, Snitily MU, Gentry-Nielsen MJ. Effect of Cirrhosis on Antibiotic Therapy in a Rat Model of Pneumococcal Pneumonia. *Diagnostic Microbiology and Infectious Diseases* 2005; 51(2):103-111.
74. Crites KA, Coffman Floreani AA, Bultsma CJ, **Olsen KM**. Staggered Interval Transition of Epoprostenol from Treprostinil in Pulmonary Arterial Hypertension. *Annals of Pharmacotherapy* 2005;39:739-743.
75. Conrad SA et al and OME-IR (SUSP)-CO3 Study Group (includes **Olsen KM**). Randomized, double-blind comparison of immediate release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. *Critical Care Medicine* 2005; 33:760-765.
76. **Olsen KM**. Use of Acid-Suppression Therapy for Management of Peptic-Ulcer Bleeding. *American Journal of Health-System Pharmacists* 2005; 62(suppl 2):S18-23.
77. **Olsen KM**. Pharmacologic Agents Associated with QT Interval Prolongation. *Flouroquinolone Safety Supplement. Journal of Family Practice.* 2005;29(suppl):S8-15
78. Devlin JE, Welage L, **Olsen KM**. Formulary Decision Process for Selection of Proton Pump Inhibitors. Part 1. *Annals Pharmacotherapy* 2005; 39:1667-1677.
79. Devlin JE, Welage L, **Olsen KM**. Formulary Decision Process for Selection of Proton Pump Inhibitors. Part II. *Annals Pharmacotherapy* 2005 39:1844-1851.

80. **Olsen KM**, Gentry-Nielsen MJ, Preheim LC. Effect of Ethanol on the Efficacy of Levofloxacin, Moxifloxacin and Trovafloxacin in a Pneumococcal Pneumonia Model. *Antimicrobial Agents and Chemotherapy*. 2006; 50(1): 210-219.
81. Devlin JW, Bakashi A, Bungay K, **Olsen KM**. An *In Vitro* Comparison of Different Providers to Deliver Four Proton Pump Inhibitor Products through a Feeding Tube. *Alimentary Pharmacology and Therapeutics* 2006; 24:1603-1611.
82. Kane S, Rebeck JA, **Olsen KM**, et al. Evaluation and Treatment Outcomes of Aspiration Syndromes in Adult Critically Ill Patients. *Annals of Pharmacotherapy* 2007; 41:321-326.
83. Nissen SW, **Olsen KM**. Selection of Proton Pump Inhibitors for Formulary Inclusion: Making Decisions Based on Appropriate Criteria. *Disease Management and Health Outcomes*; 2007: 15(5):289-298.
84. **Olsen KM**, Devlin JW. Comparison of Enteral and Intravenous Lansoprazole Pharmacodynamic Response in Critically Ill Patients. *Alimentary Pharmacology and Therapeutics* 2008; 28:326-333.
85. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, **Olsen KM**. Statins reduce mortality in septic patients. *Pharmacotherapy* 2009;29:621-630.
86. **Olsen KM**, Hitzeman ML. Dexlansoprazole MR in the management of gastroesophageal reflux disease. *Clinical Medicine: Therapeutics* 2009;1:1641-1652.
87. McGuire TR, Dobesh PP, Rupp ME, **Olsen KM**. Clinically important interaction between statin drugs and *Clostridium difficile* toxin. *Medical Hypothesis* 2009; 73:1045-1047.
88. Winterboer TM, Lecci KA, **Olsen KM**. Alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients. *Journal of Pharmacy Practice* 2010;23:6-18.
89. Nissen SW, **Olsen KM**. Treatment Algorithms in Critical Care. Do They Improve Outcomes? *Journal of Pharmacy Practice* 2010;23:61-68.
90. **Olsen KM**, Ng TMH. Infectious Diseases in the Critically Ill. *Journal of Pharmacy Practice* 2010;23:5.

91. Ng TMH, **Olsen KM**, McCartan MA, Speidel KM, Miller MA. Pharmacologic predictors of QTc prolongation and proarrhythmia in the adult medical intensive care unit. *Journal of Pharmacy Practice* 2010;23:19-24.
92. Dobesh PP, Swahn SM, Peterson EJ, **Olsen KM**. Statins in sepsis. *Journal of Pharmacy Practice* 2010;23:38-49.
93. Metz DC, Fulda G, **Olsen KM**, Monyak JT, Simonson S, Sostek MB. Rapid onset of intragastric acid control with intravenous esomeprazole in critically ill patients. *Current Medical Research and Opinion* 2010;26:1141-1148.
94. Lat I, Micek S, Janzen J, Cohen H, **Olsen KM**, Haas C. Off-label Medication Use in Adult Critical Care Patients. *Journal of Critical Care*; 2011;26:89-94
95. Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, **Olsen KM**. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate *Staphylococcus aureus* in clinical methicillin-resistant *S. aureus* isolates. *Journal of Clinical Microbiology* 2011;49(1):269-274.
96. Bogard KN, Peterson NT, Plumb TJ, Erwin MW, Fuller PD, **Olsen KM**. Antibiotic dosing during sustained low-efficiency dialysis special considerations in adult critically ill patients. *Special considerations in critically ill patients. Critical Care Medicine* 2011;39:560-570.
97. Knapp KK, Manolakis M, Webster AA, **Olsen KM**. Projected Growth in Pharmacy Education and Research, 2010 to 2015. *American Journal of Pharmaceutical Education* 2011;75 (6) (article 108):1-7.
98. Coopersmith CM, Wunsch H, Fink MP, Linde-Zwirble WT, **Olsen KM** et al. A comparison of critical research funding and the financial burden of critical illness in the United States. *Critical Care Medicine* 2012; 40:-1079.
99. Balas MC, Vasilevskis EE, Burke WJ, Boehm L, Pun BT, **Olsen KM**, Peitz GJ, Ely EW. Critical care nurses' role in implementing the "ABCDE bundle" into practice. *Critical Care Nurse* 2012;32(2):35-47.
100. Bratzler DW, Dellinger EP, **Olsen KM**, Perl T, Auwaerter PG, Bolon MS, Fish DN, Napolitano LM, Sawyer R, Slain D, Steinberg J, Weinstein RA. Antimicrobial Prophylaxis in Surgery: Clinical Guidelines from the American Society of Health Systems Pharmacists, the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, and the Surgical Infection Society.

- American Journal of Health-Systems Pharmacists. American Journal of Health-System Pharmacists 2013; 70:195-283.
101. Fuller PD, Peters LL, Hoel R, Baldwin JN, **Olsen KM**. Preceptor development and evaluation: a new approach. American Journal of Health-System Pharmacists. 2013;70(15):1605-1608.
 102. Balas MC, Burke WJ, Gannon D, Cohen MZ, Colburn L, Bevil C, Franz D, **Olsen KM**, Ely EW, Vasilevskis EE. Implementing the ABCDE Bundle into Everyday Care: Opportunities and Challenges. Critical Care Medicine 2013; 41(Suppl.):S116-127.
 103. Peitz GJ, Balas MC, **Olsen KM** et al. Top 10 Myths Regarding Sedation and Delirium in the ICU. Critical Care Medicine 2013; 41:(Suppl.):S46-55.
 104. Barletta J, Lat I, Micek S, Cohen H, **Olsen K**, Haas C. Off label use of gastrointestinal medication in the intensive care unit. Journal of Intensive Care Medicine Care 2013 Dec 20 [Epub ahead of print].
 105. Balas MC, Vasilevskis E, **Olsen KM**, Schmid K, Shostrom V et al. Effectiveness and Safety of the Awakening Breathing Coordination, Delirium and Early Mobility Bundle. Critical Care Medicine 2014; 42(4):1024-1036.
 106. McGuire TR, Dobesh P, Klepser DG, Kalil AC, **Olsen K**. Reduction in toll-like receptor-4 (tlr-4) on blood mononuclear cells after 3 weeks of rosuvastatin treatment in healthy male subjects. Current Pharmaceutical Design 2014; 20:1156-1160.
 107. Dobesh P, **Olsen KM**. Statins role in the prevention and treatment of sepsis. Pharmacological Research; 2014: Pharmacological Research 88 (2014) 31–40.
 108. Justo JA, Gauthier T, Scheetz M, Chahine E, Bookstaver PB, Gallagher J, Hermsen E, DePestel D, Ernst E, Jacobs D, Esterly J, Suda K, **Olsen KM**, Abbo LM, MacDougall C. Knowledge and attitudes of doctor of pharmacy students regarding the appropriate use of antimicrobials. Clinical Infectious Diseases; 2014:2014;59(Suppl 3):S162-S170.
 109. Gross AE, Van Schooneveld TC, **Olsen KM**, Rupp ME, Buie TH, Forsung E, Kalil AC. Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Healthcare-Associated Pneumonia. Antimicrobial Agents and Chemotherapy;2014;58:5262-5268.

110. Sankaranarayanan J, Reardon T, **Olsen KM**. Correlates and economic outcomes of proton pump inhibitor use by routes in intensive care unit patients. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2014;14(5):741-749
111. McGuire TR, Reardon NT, Bogard K, Plumb TJ, Bultsma CJ, Nissen SW, Fuller PD, **Olsen KM**. IL6 Plasma Concentrations in Patients with Sepsis Receiving SLED and Antibiotics: A Predictor for Survival. *IN VIVO* 2014;28(6):1131-1134.
112. Wang T, Benedict N, **Olsen KM**, Luan R, Zhu X, Tang H, Yan Y, Yao P, Shi L. Effect of critical care pharmacist's interventions on medication errors: systematic review of observational studies. *Journal of Critical Care* 2015: doi:10.1016/j.jrc.2015.06.018.
113. Thomas Z, Bandali F, Sankaranarayanan J, Reardon T, **Olsen KM**. A Multicenter Evaluation of prolonged empiric antibiotic therapy in adult intensive care units in the United States. *Critical Care Medicine*. 2015; 43:2527-2534.
114. Scarsi KK, Prinz EA, Synder HK, **Olsen KM**, Zhang L. The Evolution and Practice of Clinical Pharmacy in the United States. *China Pharmacy*. 2015;26:3601-3611.
115. Jin, H; Wang, T; Falcione, BA.; **Olsen, KM**; Chen, K; Tang, H; Hui, John; Zhai, S. Trough concentration of voriconazole and its relationship with efficacy and safety: a meta-analysis. *Journal of Antimicrobial Chemotherapy* 2016; doi:10.1093/jac/dkw045.
116. Huang LL, Van Schooneveld TC, Huang RH, **Olsen KM**, Rupp ME, Gross AE. Guideline-concordant versus discordant anti-infective therapy in patients with complicated intra-abdominal infections (CIAI). *Infection Control and Hospital Epidemiology*. 2016;37(7):855-8.
117. Bauer S, Barletta J, Brophy G, Erstad B, Gonzales J, Haas C, MacLaren R, Mueller E, **Olsen K**, Lat I. Development and growth of the Critical Care Clinical Trials Network. *Am J Health-Syst Pharm*. 2017;74:287-93.
118. Njoku JC, Vanschooneveld TC, Rupp ME, **Olsen KM**, Qui F, Meza JL, Hermsen ED. Lack of benefit with combination therapy versus monotherapy for the treatment of *Clostridium difficile* infection. *Infection Control and Hospital Epidemiology*. 2017;1-4. <https://doi.org/10.1017/ice.2016.320>
119. Annane D, Pastores S, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Gianfranco U, **Olsen KM**, Rochweg M,

- Rodgers SC, Russell JA, Van den Berghe G. Critical Illness-Related Corticosteroid Insufficiency (CIRCI): A Narrative Review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). *Intensive Care Medicine* 2017;43(12):1751-1763. *Critical Care Medicine* 2017;45(12):2078-2088.
120. Annane D, Pastores S, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Gianfranco U, **Olsen KM**, Rochweg M, Rodgers SC, Russell JA, Van den Berghe G. Guidelines for the diagnosis and management of critical illness related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM): 2017 *Intensive Care Medicine* 2017;43(12):1781-1792. *Critical Care Medicine* 2017;45(12):2089-2098.
 121. Annane D, Ouanes-Besbes L, de Backer D, DU B, Gordon A, Hernandez G, **Olsen K**, Osborn T, Peake S, Russel JA, Cavazzoni SZ. A global perspective on vasoactive agents in shock. *Intensive Care Medicine*. 2018;44(6):833-846. <https://doi.org/10.1007/s00134-018-5245-5>.
 122. Lat I, Ryan S, Daley MJ, Seton D, Shewale A, Pangrazzi MH, Hammond DA, **Olsen KM**. A multicenter, prospective, observational study to determine the predictive factors for multidrug resistant pneumonia in critically ill adults: The DEFINE study. *Pharmacotherapy*. 2018;44(12):2171-2180. doi: 10.1002/phar.2171
 123. Nazer LH, Elaibaid M, Al-Qadheeb N, Kleinpell R, **Olsen KM**, Hawari F. Critical care Research in the World Health Organization eastern Mediterranean region over two decades: Where do we stand? *Intensive Care Medicine*; 2018;44(9):1588-1590.
 124. Yeo QM, Hammond DA, **Olsen KM**. Impact of chronic hypertension on time to goal mean arterial pressure and clinical outcomes in critically ill patients with septic shock requiring vasopressors. *Journal of Critical Care* 2019;49:143-148.
 125. Annane D, Lerolle N, Meuris S, Sibilla J, **Olsen KM**. Academic Conflict of Interest. *Intensive Care Medicine*. 2019; 45(1):13-20.
 126. Elaibaid M, Nazer LH, Shaikha L, Al-Qadheeb N, Kleinpell R, **Olsen KM**. Evaluating the published critical care research from the World Health Organization Eastern Mediterranean region. *BMC Res Notes* 2019;12:32. <https://doi.org/10.1186/s12104-019-4093-7>.

127. Klepser DG, Klepser ME, Murry JS, Borden H, **Olsen KM**. Evaluation of a community pharmacy-based influenza and group A streptococcal pharyngitis disease management program using polymerase chain reaction point-of-care testing. *Journal of the American Pharmacists Association* 2019;59:872-879.
 128. Martin N, Peitz GJ, **Olsen KM**, Merritt HM. Lower Opioid Doses are Required with hydromorphone Compared to Fentanyl in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). *ASAIO Journal* 2020; DOI:0.1097/MAT.0000000000001253.
 129. Nazer LH, Kleinpell R, **Olsen KM**, Hawari F. Commentary: A capacity-building program to increase critical care research productivity in the Middle East Region. *Critical Care Explorations* 2021; Letter DOI: 10.1097/CCE.0000000000000315.
 131. **Bergman SJ**, Cennimo DJ, Miller MM, Olsen KM. Treatment of Coronavirus Disease 2019 (COVID-19): Investigational Drugs and Other Therapies. *Medscape Drugs and Diseases*. First posted online March 2020 and updated regularly during the pandemic.
 132. Kleinpell R, Grabenkort R, Boyle W, Vines D, **Olsen KM**. Interprofessional practice in critical care. *Critical Care Medicine*. 2021 in press.
- Franz DD, **Olsen KM**, Balas MC et al. Medication exposure and delirium among Intensive Care Unit Patients in a delirium-prevention protocol cohort. In review

Other Publications/Non-Peer Reviewed

1. **Olsen KM**. Prevention of surgical site infections: improving compliance with the surgical care improvement project measures. *MedScape Infectious Diseases WEB MD* <http://www.medscape.com/viewarticle/705366?src=mp&spon=30&uac=3417AX> 07/14/2009.
2. **Olsen KM**. Point-of-Care Testing by Pharmacists. *AR-Rx. The Arkansas Pharmacist*. January 2016.
3. **Olsen KM**. Implementation Sciences. *AR-Rx. The Arkansas Pharmacist*. April, 2016.
4. **Olsen KM**. Integrating Medication Therapy Management into the Workflow. *AR-Rx. The Arkansas Pharmacist*. January, 2017.
5. **Olsen KM**. Community Pharmacy Residencies. *AR-Rx. The Arkansas Pharmacist*. April, 2017.

6. **Olsen KM**. Observations from Academia. AR-Rx. The Arkansas Pharmacist. October, 2017.
7. **Olsen KM**. Student Leadership in Community Pharmacy. AR-Rx. The Arkansas Pharmacist. January, 2018.
8. **Olsen KM**. Leaders Recognize the Value of People. AR-Rx. The Arkansas Pharmacist. April, 2018.
9. **Olsen KM, Mercer J**. 2018 UAMS and Harding Colleges of Pharmacy Salary Survey. AR-Rx. The Arkansas Pharmacists, September, 2018; pgs 21-23.

BOOKS

1. **Olsen KM**, Nithman CH, Keller BH, Mason AE, Thompson DT. A Laboratory Manual for Clinical Pharmacy. Southwestern Oklahoma State University, Weatherford, Oklahoma.
2. Job Descriptions and Contracts in Critical Care. Society of Critical Care Medicine, Chicago, IL **Olsen KM** (task force chair), 2005, 1ST ed.
3. Handbook of Intravenous Drug Administration in Critically Ill Patients. 2nd Edition. Ed. Steve Martin, **Keith M. Olsen**, Greg Susla. 2007, Society of Critical Care Medicine.

BOOK CHAPTERS

1. **Olsen KM**, D`Oria L. Uterine Motility Agents. In: Baer CL, Williams BR, eds. Clinical Pharmacology and Nursing, 1st Ed. Springhouse, Pennsylvania: Springhouse Publishing Company; 1988:960-970.
2. **Olsen KM** (contributor), In: Belcher ML, Ed., House Officer's Pocket Drug Reference, 1st ed. 1989.
3. **Olsen KM** (contributor), In: Belcher ML, Ed., Essentials of Pharmacology 2nd ed. 1993.
4. **Olsen KM** (Clinical Pharmacology Contributor/consultant), In: Skidmore-Roth L., Mosby's 1989 Nursing Drug Reference. St. Louis, C.V. Mosby Company.

5. **Olsen KM**, D`Oria L. Uterine Motility Agents. In: Baer CL, Williams BR, eds. Clinical Pharmacology and Nursing, 2nd Ed. Springhouse, Pennsylvania: Springhouse Publishing Company; 1991:960-970.
6. **Olsen KM**, Schaubin J, Watson W, Rose SR, Todd M. Hospital Pharmacy Teleconference Highlights: Q&A. (Mazicon Round table, Flumazenil: The Pharmacists Perspective). Excerpta Medica, Princeton, NJ.1993.
7. Clinical Pharmacology Made Easy. Contributor. Springhouse, Pennsylvania: Springhouse Publishing Company. 2000.
8. **Olsen KM** (Committee Chair), Job Description and Contracts in Critical Care. Society of Critical Care Medicine, Des Plaines, IL. 2004.
9. **Olsen KM**. Theophylline and other Methylxanthines. Chapter 197 in Textbook of Critical Care, 5th Edition. Ed Mitchell Fink, Edward Abraham, Jean-Louis Vincent, Patrick Kochanek. 2005; pp 1683-1687.
10. 2005 Nursing Spectrum Drug Handbook. Dallas, TX Contributor.
11. Injectable Drug Handbook, 2nd ed. 2008 Society of Critical Care Medicine, Des Plaines, IL, Eds. Steven J. Martin, **Keith M. Olsen**, Gregory M. Susla.
12. **Olsen KM**, Chisholm MA, Jackson MW. Chapter 31. Evaluation of the Gastrointestinal Tract. In Pharmacotherapy: A Pathophysiology Approach, 7th Edition. Eds. DiPiro, Talbert, Yee, Matzke, Wells, Posey. 2008.
13. **Olsen KM**, Hutchins G. Chapter 33. Evaluation of the Gastrointestinal Tract. In Pharmacotherapy: A Pathophysiology Approach, 8th Edition. Eds. DiPiro, Talbert, Yee, Matzke, Wells, Posey. 2011
14. **Olsen KM**. Theophylline and other Methylxanthines. Chapter 181 in Textbook of Critical Care, 6th Edition. Ed Mitchell Fink, Edward Abraham, Jean-Louis Vincent, Patrick Kochanek. 2011;1339-1341.
15. **Olsen KM**. Nonsteroidal anti-inflammatory agents. Chapter 183 in Textbook of Critical Care, 6th Edition. Ed Mitchell Fink, Edward Abraham, Jean-Louis Vincent, Patrick Kochanek. 2011; 1346-1353.
16. Peitz GJ, **Olsen KM**. Acute Kidney Injury and Renal Replacement Therapy. Chapter 11 in Critical Care Pharmacotherapeutics, 1st Edition. Ed Thomas Johnson. 2012;215-243.

17. **Olsen KM** (Contributor/consultant), In: Patricia Dwyer Schull: Nurse's Drug Handbook, 7th ed, 2013. McGraw-Hill.
18. **Olsen KM**, Hutchins G. Chapter 38. Evaluation of the Gastrointestinal Tract. In Pharmacotherapy: A Pathophysiology Approach, 8th Edition. Eds. DiPiro, Talbert, Yee, Matzke, Wells, Posey. 2014 epublication.
19. **Olsen KM**, Gross AE. DiPiro JT. Chapter 91. Intraabdominal Infections. In Pharmacotherapy: A Pathophysiology Approach, 8th Edition. Eds. Dipiro, Talbert, Yee, Matzke, Wells, Posey. 2014:1821-1834.
20. **Olsen KM**, Peitz G. Antimicrobial Prophylaxis. In Critical Care Pharmacotherapy, 1st Edition. Editor Brian Erstad. 2016: Chapter 18:351-361.
21. **Olsen, Keith M** and McCaleb Rachael V. Evaluation of the Gastrointestinal Tract. Chapter e31. In: Pharmacotherapy: a pathophysiologic approach. Editors Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey. 10th edition New York: McGraw-Hill Education; 2017. P433.
22. Gross, Alan E., **Olsen, Keith M**. Intra-Abdominal Infections. Chapter 114. In: Pharmacotherapy: a pathophysiologic approach. Editors Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey. 10th edition New York: McGraw-Hill Education; 2017. P1813-1825.
23. **Olsen, Keith M** and McCaleb Rchael V. Evaluation of the Gastrointestinal Tract. Chapter 428e. In: Pharmacotherapy: a pathophysiologic approach. Editors Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey. 11th edition New York: McGraw-Hill Education; 2020. 461.
22. Gross, Alan E., **Olsen, Keith M**. Intra-Abdominal Infections. Chapter 132. In: Pharmacotherapy: a pathophysiologic approach. Editors Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey. 11th edition New York: McGraw-Hill Education; 2020. 1939-1954.
23. **Olsen KM**, Peitz G. Antimicrobial Prophylaxis. In Critical Care Pharmacotherapy, 2nd Edition. Editor Brian Erstad. 2021:press.

VIDEO'S/TELECOMMUNICATIONS/QUOTAIONS

1. KVXO, Oklahoma City TV station. Hazards of the Over-the-Counter diet aides. May, 1983.
2. Live Broadcast/Video Symposium, Flumazenil Hospital Pharmacy Roundtable, New York, NY, September 1992.
3. Live Broadcast/Video Symposium, Acid Disease, Wal-Mart Television Network, Bentonville, Arkansas, June, 1994.
4. LifeQuest, University of Nebraska Medical Center Health Education Program. Fall 1998.
5. Researchers study new drugs to fight antibiotic resistant bacteria. Feature Keith Olsen and Mark Rupp. Synapse, University of Nebraska Medical Center, Summer 1998.
6. Researcher investigates resistant strains of bacteria in inter-disciplinary study. New Scripts. College of Pharmacy Alumni Newsletter, Summer 1998.
7. UNMC Tests Antibiotic Alternatives. UNO Gateway, Omaha, NE Feature article. October 16, 1998.
8. ICU Pharmacists Facing Life-and-Death Challenges. Special Report. Hospital Pharmacists Report, June 2000. Quotation.
9. Survival Strategies for Your New Career. American Society of Health-System Pharmacists. 2002, 1st ed., Practioner Spotlight. Acute Care: Keith M. Olsen.
10. CDC, CMS joining forces to prevent surgical infections. Hospital Practice. Drug Topics. Com., June 2002. Quotation.
11. KVNO Public Broadcast Radio. Pharmaceutical Treatments of Gastroesophageal Reflux Disease. UNMC Radio Program, August, 2005.
12. KETV-ABC, Omaha, NE. Medical piece at prime time; Health Watch: Airborne Cold Prevention Tested. January 16, 2005, News at 10.
13. Antibiotics and drug resistant bacteria. Holdrege Press newspaper. October, 2005.

14. Drug Dangers Lurk in the ICU. Pharmacy Practice News. Highlights from the Society of Critical Care Medicine Annual Meeting. April, 2006.
15. SCCM: Initial Antibiotic Choice Important in Ventilator-Associated Pneumonia. MedPage Today, 2008.
16. Should you worry about drug side effects? WWW.KETV.com/health/162114801/detail.html, 2008.
17. VAPOR Trial Lifts Veil on Ventilator Pneumonia. Pharmacy Practice News, April 01, 2008.
18. VAPOR Trial Lifts Veil on Ventilator-Associate Pneumonia. General Surgery News, June 01, 2008.
19. Sedation Order Form May Reduce ICU Stays. Anesthesiology News, July 01, 2008.
20. Nation continues to try to prevent surgical complications, deaths. Am J Health-Syst Pharm, Vol 68, Oct 1, 2011.
21. ABCDE Trial. Reuters Health, 2013-01-25.

ABSTRACTS/POSTERS

1. Milenkocovich L, Peitz GJ, Pfeifer C, Olsen KM, Klepser D. Comparison of Bivalirudin Versus Heparin as Primary Anticoagulation Bridging Post-LVAD Implantation. 2020 Critical Care Congress, Orlando FL
2. Klepser D, Klepser M, Olsen KM. Treatment Patterns Resulting from a Community Pharmacy-Based Disease Management Service, Utilizing Real Time PCR Testing for Influenza and Group A Streptococcus. MAD-ID 2019, Orlando, FL
3. Lat I, Daley MJ, Pangrazzi M, Hammond D, Shewale A, **Olsen KM**. Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Patients: The DEFINE Study. Society of Critical Care Medicine Congress. Critical Care Medicine, San Antonio, TX 2018.
3. Lat I, Kelley K, Hammond D, Pangrazzi M, Daley MJ, **Olsen KM**. The incidence of multidrug resistant pneumonia in critically ill patients receiving proton pump

- inhibitors vs histamine H2 receptor antagonists for stress ulcer prophylaxis. American College of Clinical Pharmacy. Phoenix, Arizona, October 2017.
4. Yeo QM, Hammond D, **Olsen KM**. Impact of chronic hypertension on time to goal mean arterial pressure and clinical outcomes in critically ill patients with septic shock requiring vasopressors. ESICM LIVES 2017, 30th Annual Congress, Vienna, Austria, 23-27 September 2017.
 5. Heldenbrand SD, Flowers SK, Neill KK, Warmack S, Franks AM, **Olsen KM**. Improving the multiple mini-interview process for a more holistic applicant review. American Association of Colleges of Pharmacy, Annual Meeting, Anaheim, CA July 2016.
 6. Oetken, H, Peitz G, **Olsen KM**. The impact of early analgesia on outcomes in mechanically ventilated patients. *Crit Care Med* 2015;43(suppl):624A.
 7. Aker K, Peitz G, **Olsen KM**. Outcomes associated with antibiotic desensitization in critically ill patients. *Crit Care Med* 2015;43(suppl):459A.
 8. Austin M, Peitz G, **Olsen K**, Van Schooneveld T. Evaluation of procalcitonin utilization in septic patients in an academic intensive care unit. *Crit Care Med* 2014;42(Suppl.):481A.
 9. Samarin M, Sullivan J, **Olsen K**, Peitz G. The impact of emergency room sedation on ICU outcomes. *Crit Care Med* 2014;42(Suppl.):554A.
 10. Luc M, Austin M, Peppard W, Peitz G, Huang A, **Olsen K**. Pharmacokinetic analysis of once-daily vancomycin dosing during continuous renal replacement therapy. *Crit Care Med* 2014;42(Suppl.):626A.
 11. Gross AE, Van Schooneveld T, **Olsen KM**, Rupp ME, Kalil AC. Predictors of 30-day hospital readmission in patients with community-onset pneumonia. International Conference on Antimicrobial Agents and Chemotherapy, September 2014.
 12. Dering-Anderson A; Klepser D; Klepser MI; **Olsen K** Determining the Need for a Point-of Care, Rapid Diagnostic Testing Elective; poster. AACCP; July 2014; Grapevine, Texas.
 12. Dobesh PP, Klepser DG, McGuire TR, Roberts D, Himmelberg A, **Olsen KM**. Impact of obesity on outcomes in patients with sepsis. International Conference

- on Critical Care and Emergency Medicine. Brussels, Belgium, March 2014 Abstract 46.
14. Dobesh PP, Klepser DG, McGuire TR, Roberts D, Himmelberg A, **Olsen KM**. Blood product transfusions in septic patients are associated with mortality, ARDS, and more days on mechanical ventilation. International Conference on Critical Care and Emergency Medicine. Brussels, Belgium, March 2014 Abstract 111.
 15. Dobesh PP, Klepser DG, McGuire TR, Roberts D, Himmelberg A, **Olsen KM**. Does Clopidogrel change morbidity and mortality in ICU sepsis patients? International Conference on Critical Care and Emergency Medicine. Brussels, Belgium, March 2014 Abstract 238.
 16. **Olsen KM**, Reardon N, Plumb T, Bogard K, Peitz GJ, Branch-Woods AB. Pharmacodynamics and pharmacokinetics of ciprofloxacin during sustained low-efficiency dialysis. International Conference on Critical Care and Emergency Medicine. Brussels, Belgium, March 2014.
 17. Peitz GJ, Dvoracek KD, Sankaranarayanan J, Balas MC, **Olsen KM**. Awakening and breathing coordination, delirium monitoring and early mobility bundle: A preliminary cost analysis. International Conference on Critical Care and Emergency Medicine. Brussels, Belgium, March 2014.
 18. Franz DD, **Olsen KM**, Balas M, Lander L, Schmid K, Shostrom V, Burke WJ. Psychoactive Medication administration and Delirium Prevalence and Duration in ICU Patients. *Critical Care Medicine* 2013;41(12, Suppl):662A.
 19. Nedved A, VanSchooneveld TC, Sayles H, **Olsen KM**, Rupp ME, Gross AE. Does Procalcitonin (PCT) Use Decrease Duration of Therapy for Community-Acquired (CAP) and Healthcare-Associated Pneumonia (HCAP) in an Uncontrolled Setting? International Conference on Antimicrobial Agents and Chemotherapy - International Conference on Antimicrobial and Chemotherapy 2013:K1716.
 20. Gross AE, VanSchooneveld TC, Rupp ME, **Olsen KM**, Bui H, Forsung E, Kalil AC. Epidemiology and Predictors of Multidrug-Resistant (MDR) Community-Acquired (CAP) and Healthcare-Associated Pneumonia (HCAP) at a Midwest Academic Medical Center: A Propensity Score Case-Cohort Study. International Conference on Antimicrobial Agents and Chemotherapy - ICAAC 2013:K-1399

21. Kesteloot LL, VanSchooneveld TC, Sayles H, Huang R, **Olsen KM**, Rupp ME, Gross AE. Does Guideline-Concordant versus Discordant Anti-infective Use in Patients with Complicated Intraabdominal Infections (CIAI) Affect Patient Outcomes? IDWeek 2013:A218.
22. Dering-Anderson A, Klepser M, Klepser DE, Klepser S, **Olsen KM**. A Rapid Diagnostic Test Certificate Program for Community Pharmacists. American Association of Colleges of Pharmacy 2013.
23. Balas M, **Olsen K**, Gannon D, Sisson J, Sullivan J, Stothert J, Jawa R, Vasilevskis E, Ely W. Safety and efficacy of the ABCDE bundle in critically-ill patients receiving mechanical ventilation. 43rd Critical Care Congress. Critical Care Medicine 2012;40(12 Suppl):A1.
24. **Olsen K**, Burke W, Peitz G, Gannon D, Stothert J, Jawa R, Nuss S, Thorell W, Freihaut F, Balas M. The ABCDE bundle reduces the incidence of delirium in non-mechanically ventilated patients. 43rd Critical Care Congress. Critical Care Medicine 2012;40(12 Suppl):A5.
25. Reardon N, **Olsen K**, Bogard K, Plumb T, Yin L, Nissen S, Fuller P, Bultsma C, BranchWoods A, Peitz G. Pharmacokinetics of vancomycin during sustained low-efficiency dialysis. 43rd Critical Care Congress. Critical Care Medicine 2012;40(12 Suppl):A51.
26. Dvoracek K, Nissen S, Peitz G, Sankaranarayanan J, **Olsen K**. Comparison of continuous infusion versus bolus sodium phosphate in sustained low efficiency dialysis. 43rd Critical Care Congress. Critical Care Medicine 2012;40(12 Suppl):A468.
27. Dobesh P, Klepser D, McGuire T, Weber J, Schneider S, **Olsen K**. Impact of clopidogrel exposure on outcomes in patients with sepsis. 43rd Critical Care Congress. Critical Care Medicine 2012;40(12 Suppl):A518.
28. Buckley M, **Olsen K**, Frazee E, Juan P, Roberts R, Dzierba A, Bauer S, Peitz G. An evaluation of vancomycin in critically ill obese patients requiring continuous renal replacement therapy. 43rd Critical Care Congress. Critical Care Medicine 2012;40(12 Suppl):A942.
29. Dobesh P, Klepser D, McGuire T, Weber J, Schneider S, **Olsen K**. Transfusions in septic patients are associated with ARDS and increased mechanical ventilation days. 43rd Critical Care Congress. Critical Care Medicine 2012;40(12 Suppl):A1013.

30. Brink H, Peitz G, Klepser D, **Olsen K**. Comparison of dexmedetomidine as adjunct therapy to benzodiazepines vs. standard benzodiazepine therapy in treatment of alcohol withdrawal syndrome. 43rd Critical Care Congress. Critical Care Medicine 2012;40(12 Suppl):A1027.
31. Fuller PD, Peters LL, Hoel R, Baldwin JN, **Olsen KM**. Preceptor development and evaluation: A new approach. National Preceptor's Conference 2012, Washington, DC.
32. Njoku JC, VanSchooneveld TC, Rupp ME, Qui F, Meza JL, **Olsen KM**, Hermsen ED. Evaluation of combination vs. monotherapy for Clostridium difficile infection (CDI). International Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract 1550.
34. Thomas Z, Bandali F, Sankaranarayanan J, Reardon T, **Olsen KM**. A multicenter evaluation of prolonged empiric antibiotic therapy in adult intensive care units in the United States. 42nd Critical Care Congress. Critical Care Medicine 2012;39 (suppl):291A.
35. Bandali F, Thomas Z, Sankaranarayanan J, Reardon T, **Olsen KM**. Prevalence and risk factors associated with prolonged surgical prophylaxis analysis from the prolonged empiric antibiotic therapy study. 42nd Critical Care Congress. Critical Care Medicine 2012;39 (suppl):297A.
36. Dobesh P, Klepser D, McGuire T, Bailey K, Brink H, Schneider S, Weber J, **Olsen KM**. Statins and ACE inhibition in prevention of ARDS. 42nd Critical Care Congress. Critical Care Medicine 2012;39 (suppl):351A
37. Barletta J, Lat I, Micek S, Cohen H, **Olsen K**, Haas C. Off label use of gastrointestinal medication in the intensive care unit. 42nd Critical Care Congress. Critical Care Medicine 2012;39 (suppl):730A.
38. McGuire TR, Dobesh P, Klepser DG, Kalil AC, **Olsen K**. Reduction in toll-like receptor-4 (tlr-4) on blood mononuclear cells after 3 weeks of rosuvastatin treatment in healthy male subjects. ACCP Annual Meeting 2012, Hollywood, FL, October 21-24, 2012 (Abstract #159)
39. **Olsen KM**, Pitz A, Branch-Woods A, Crotty M, Preheim L. A novel method for comparison of microbiologic growth in intravascular devices: Evaluation of three devices. International Conference on Antimicrobial Agents and Chemotherapy. 2011:K1434A.

40. Reffert J, Dobesh PP, Klepser DG, Collier DS, **Olsen KM**, Carstens PK. Video based high-fidelity simulation improves knowledge gain. *American Journal of Pharmaceutical Education* 2011;75(5):abstract.
41. Sankaranarayanan J, Reardon T, **Olsen KM**. Patient characteristics associate with the use of enteral and parenteral acid suppressive agents in intensive care. 16th Annual International Meeting of International Society of Pharmacoeconomics and Outcomes Research (ISPOR), May 2011.
42. Peitz G, **Olsen K**, Winterboer T, Klepser D, Thorell W. Retrospective comparison of phenytoin vs. levetiracetam vs. no medication in the prevention of seizures in subarachnoid hemorrhage. 40th Critical Care Congress, San Diego, CA . *Critical Care Medicine* 2010;38:A-853.
43. Dobesh P, **Olsen K**, Klepser D, Carstens P, Collier D, Reffert J. A high-fidelity simulator learning environment improves cardiovascular critical care knowledge gain and retention. 40th Critical Care Congress, San Diego, CA . *Critical Care Medicine* 2010;38:A-493.
44. Dobesh P, Klepser D, McGuire T, Hitzeman M, **Olsen K**. ACE inhibition reduces mortality in patients with severe sepsis. 40th Critical Care Congress, San Diego, CA . *Critical Care Medicine* 2010;38:A-422.
45. **Olsen KM**, Pitz AM, Woods-Branch A, Preheim LC. Comparison of Telavancin, Ceftriaxone and Vancomycin Efficacy in a Rat Model of Pneumococcal Pneumonia. 50th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, MA September, 2010;K-1503.
46. Sankaranarayanan J, Baldwin JN, Fuller PD, Peters LL, Ridgway JE, Norman KA. **Olsen KM**. Assessing faculty and preceptors needs, preferences, workload-satisfaction, and resource use in a Midwest pharmacy college planning professional development programs. American Association of Colleges of Pharmacy Annual Meeting, Seattle, WA. July 2010.
47. Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, **Olsen KM**. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate *Staphylococcus aureus* in clinical methicillin-resistant *S. aureus* isolates. 110th General Meeting of the American Society of Microbiology 2010, San Diego, CA, Abstract 10-GM-A-1574-ASM.

48. Sankaranarayanan J, **Olsen KM**, Reardon T, Hays EM, Orwe LA. Factors associated with the use of enteral and parenteral proton pump inhibitor use in critically ill patients. 15th Annual International Meeting of International Society of Pharmacoeconomics and Outcomes Research (ISPOR), May 2010.
49. McGuire TR, Peterson NT, Bogard KN, Erwin M, Bultsma C, **Olsen KM**. Cytokine clearance during sustained low efficiency dialysis. *Critical Care Medicine* 2009;37:A436.
50. **Olsen KM**, Dobesh PP, Carstens P, Klepser DG, Collier DS. Use of an advanced patient care simulator to reinforce instruction of cardiovascular emergencies. American Association of Colleges of Pharmacy. 2009.
51. Sankaranarayanan J, Baldwin JN, **Olsen KM**. Student learning outcomes from a Medicare part d case based web-interactive engagement activity. American Association of Colleges of Pharmacy. 2009.
52. Sankaranarayanan J, Baldwin J, Ridgway J, **Olsen K**, Fletcher C, Content Mapping of Public Health in the PharmD Program for Programmatic Development - School poster presentation at the July 2008 AACP/AFPC Annual Meeting in Chicago, IL; *American Journal of Pharmaceutical Education* 2008; 72 (3) Article 72, p101; <http://www.ajpe.org/aj7203/aj720372/aj720372.pdf>
53. Lat I, Micek S, Cohen H, **Olsen K**, Haas C. Off-label Medication Use in Adult Critical Care Patients, *Crit Care Med* 2008;36:A344
54. Lat I, **Olsen K**, Micek S, Cohen H, Haas C. Off-label Medication Use is Associated with Severity of Illness. *Crit Care Med* 2008;36:A353.
55. Lat I, Cohen H, **Olsen K**, Micek S, Haas C. Proton Pump inhibitors are the primary therapy used for prophylaxis in stress related mucosal damage. *Crit Care Med* 2008;36:A680.
56. Winterboer TM, **Olsen KM**, Hermsen E, Bultsma C. Do we achieve pharmacodynamic targets with gentamicin and tobramycin in critically ill patients? *Crit Care Med* 2008;36:A677.
57. **Olsen KM** and the VAPOR Study Group. Use of an institutional specific algorithm improves initial treatment of ventilator associated pneumonia. 48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC October, 2008;K-483.

58. Dobesh PP, Klepser DG, McGuire TR, **Olsen KM**. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers reduce mortality in septic patients. *Pharmacotherapy* 2008;28.128e:46.
59. Sankaranarayanan J, Baldwin JN, Ridgway J, **Olsen KM**, Fletcher CV. Content mapping of public health in the PharmD program for programmatic development. American Association of Colleges of Pharmacy, 2008.
60. Sostek MB, Fulda G, **Olsen KM**, Monyak JT, Simonson S, Metz DC. Intravenous esomeprazole in critically ill patients. *American Thoracic Society* 2008:A40.
61. Metz DC, Fulda G, **Olsen KM**, Monyak JT, Simonson S, Sostek MB. Intra-gastric acid control with intravenous esomeprazole in critically ill patients. *Digestive Diseases Week* 2008; T1073.
62. Metz DC, Fulda G, **Olsen KM**, Monyak JT, Simonson S, Sostek MB. Rapid onset of intra-gastric acid control with intravenous esomeprazole in critically ill patients. *Accepted Digestive Disease Week* 2008; W1906.
63. **Olsen KM**, Grabarczyk J, Cano E et al. Baseline results from ventilator-associated pneumonia outcomes research (VAPOR). *Critical Care Medicine* 2007;35 (suppl):A16.
64. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, **Olsen KM**. Statins reduce mortality in septic patients. *Critical Care Medicine* 2007;35 (suppl):A280.
65. Nissen SW, Iselin EJ, Wearne, EB, **Olsen KM**. Failure to use a sedation order form results in increased ventilator days and ICU length of stay. *Critical Care Medicine* 2007;35 (suppl):A246.
66. **Olsen KM**, Devlin JW. Comparison of enteral and intravenous lansoprazole pharmacodynamic response in critically ill patients. *Critical Care Medicine* 2007;35 (suppl):A110.
67. Baksi A, Bungay K, **Olsen KM**, Devlin JW. An in vitro Comparison of Different Providers to Deliver Four Different Proton Pump Products Through a Feeding Tube, *Pharmacotherapy*, 2005;25(10):1478A.
68. TM Ng, **Olsen KM**, McCartan MA, Speidel KM, Miller MA. Pharmacologic predictors of QTc prolongation and proarrhythmia in the adult medical intensive care unit. *Critical Care Medicine*. 2004;32(12):

69. McCartan MA, Speidel KM, Miller MA, **Olsen KM**, Ng TMH. Utility of a Formal QTc Monitoring Algorithm in the Adult Intensive Care Unit. *Pharmacotherapy*; 2004; 24(10):1428:154A.
70. **Olsen KM**, Pathak R, Ng T et al. Comparison of ciprofloxacin and moxifloxacin and associated risk factors on QTc prolongation in critically ill patients. *Crit Care Med* 2003;31(supplement 2):463A.
71. Kane-Gill SL, Rea RS, **Olsen KM** et al. Evaluating the treatment of aspiration syndromes. *Crit Care Med* 2003; 31(supplement 2):475A.
72. **Olsen KM**, Hingorani V, Fuller PD, Frank WO. Effect of enteral feedings and omeprazole suspension on the assessment of occult and overt gastric bleeding. *Critical Care Medicine* 2003; 31(supplement):231A.
73. Teale G, Collier D, Horslen S, **Olsen KM**. Pharmacokinetics and Pharmacodynamics of Intravenous Pantoprazole in Critically Ill Pediatric Patients. Midwest Residency Conference, May 2002
74. Kaufman SS, Lyden ER, **Olsen KM**, et al. Omeprazole Therapy in Pediatric Patients Following Liver and Intestinal Transplants. *Crit Care Med* 2001; 29(12):A307/S113.
75. **Olsen KM**, McNabb JC, Fey PD, Rupp ME. *In vitro* Activities of Ertapenem and Parenteral β -Lactam Antibiotics against Clinical Isolates of ESBL Producing *Klebsiella pneumoniae* and in an Isogenic Host. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2001:A807.
76. **Olsen KM**, Rudis MA, Rebeck JA, Gelmont D, Mehdian R, Nelson C, Rupp ME. Effect of Single Daily Dose vs. Multiple Daily Dosing of Tobramycin on Alanine Aminopeptidase and N-acetyl- β -D-glucosaminidase Excretion. *Crit Care Med* 2000; 28(12) A101.
77. Rebeck JA, Rasmussen J, **Olsen KM**. Clinical Aspiration-Related Antimicrobial Practice Patterns in the Intensive Care Unit. *Crit Care Med* 2000; 28(12):A154.
78. Rebeck JA, Bergman KL, **Olsen KM**. *In vivo* effects of ranitidine and omeprazole on T-lymphocyte proliferation and immune-modulation. *Crit Care Med* 2000; 28(12):A183.
79. Phillips JO, **Olsen KM**, Rebeck JA, Metzler MH. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration

- compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. *Pharmacotherapy* 2000; 20 (10):A74.
80. **Olsen KM**, Preheim LC, Gentry-Nielsen M. The Pharmacodynamic Activity and Efficacy of Linezolid in a Rat Model of Pneumococcal Pneumonia. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2000; A2251.
 81. McLaren AC, McLaren SG, **Olsen KM**. Antibiotic levels in retrieved antibiotic methacrylate spacers. *Musculoskeletal Infection Society*, August, 2000.
 82. McLaren AC, McClaren SG, Nelson CL, **Olsen KM**. The elution of tobramycin from calcium pellets in a twenty-four hour period. *Musculoskeletal Infection Society*, August, 2000
 83. McClaren A, McClaren SG, Nelson CN, **Olsen KM**. The elution of tobramycin, vancomycin and cefazolin from hand-mixed calcium sulfate bio-resorbable beads. *Musculoskeletal Infection Society*, August, 2000.
 84. Rebeck JA, Yee GC, Nelson CL, et al #5. Thrombocytopenia-Associated Costs in an Adult Intensive Care Unit Population. *Crit Care Med* 1999;27(12): A94.
 85. Preheim LC, **Olsen KM**, Gentry-Nielsen MJ. Efficacy and Pharmacokinetics of Levofloxacin, Trovafloxacin, and Moxifloxacin in Ethanol-Fed Rats with Experimental Pneumococcal Pneumonia. *Clin Infect Dis* 1999; 29(4):73A.
 86. Bergman KL, Kaufman SS, Collier DC, **Olsen KM**. Pharmacokinetics/Pharmacodynamics of Omeprazole Suspension in Critically Ill Pediatric Liver/Intestinal Transplant Patients. *Pharmacotherapy* 1999; 19:1213.
 87. Rebeck JA, Fey PD, Bergman KL, **Olsen KM**. *In Vitro* Activities of Parenteral β -Lactam Antimicrobial Agents against TEM-10, TEM-26, and SHV-5 Derived Extended Spectrum Beta-Lactamases. *Clin Infect Dis*, 1999; 29(4):982.
 88. **Olsen KM**, Rebeck J, Rupp ME. Arthralgia and Myalgia Related to Quinupristin/Dalfopristin Administration. *Clin Infect Dis* 1999; 29(4):1001.
 89. Rebeck JA, Fey PD, **Olsen KM**, Rupp ME. Characterization of an Extended-Spectrum Beta-Lactamase (ESBL) Outbreak in a Pediatric Intensive Care Unit (PICU) Solid-Organ Transplant Population. In Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 1999; p. 614 [abstract 1177].

90. McLaren SG, Nelson CL, Wassell DI, **Olsen KM**. The Effect of Sampling Methods on Antibiotic Elution of Tobramycin from Calcium Sulfate. Musculoskeletal Infectious Diseases Society August 1999, Snowmass, Colorado.
91. McLaren SG, Skinner RA, Nelson CL, **Olsen KM**. Treatment of Experimental Osteomyelitis with Calcium Sulfate Pellets Containing Tobramycin. European Federation of Orthopaedics and Traumatology June 1999, Brussels, Belgium.
92. Phillips JO, Metzler M, **Olsen KM**. Stability of Simplified Lansoprazole Suspension (SLS). Gastroenterol 1999; 116(4) A: G0382.
93. McLaren SG, Skinner RA, Nelson CL, et al #6. Treatment of Experimental Osteomyelitis with Calcium Sulfate Pellets Containing Tobramycin. American Academy of Orthopaedic Surgeons 1999, Anaheim, California.
94. Bergman KL, Kaufman S, Collier DC, Rebeck JA, **Olsen KM**. Pharmacodynamics of Omeprazole Suspension in Critically Ill Pediatric Liver/Intestinal Transplant Patients. Critl Care Med 1999; 26:A171.
95. DiGiacinto JL, Bergman KL, Hoie EB, **Olsen KM**. Stability of Liquid Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Syringes. Inter Pharmaceut Abs 1998;35(21): 3513051.
96. Preheim LC, **Olsen KM**, Gentry MJ, Snitily MU. Efficacy and Pharmacokinetics of Ciprofloxacin, Liposomal Ciprofloxacin, and Ceftriaxone in Rats with Pneumococcal Pneumonia. Clin Infect Dis 1998; 27:A259.
97. Monaghan MS, Marx MA, **Olsen KM**, et al. Correlation and Prediction of Phenytoin Binding Using Standard Laboratory Parameters in Patients Following Renal Transplantation. Pharmacotherapy 1998; 18(5):1167.
98. Hickmon SG, Nelson CL, Skinner RA, et al #6. Treatment of Experimental Osteomyelitis with Calcium Sulfate Pellets Containing Tobramycin Sulfate. Musculoskeletal Infection Society 1998, St. Louis, Missouri
99. Rupp ME, Sisson JH, Peterson D, et al #6. Ventilator Associated Pneumonia (VAP): Risk Factors and Outcome Assessment. Infect Control Hosp Epidemiol 1998; 19:S22.
100. Preheim LC, Gentry MJ, Mei Y, **Olsen KM**. Efficacy and Pharmacokinetics of Azithromycin (AZI), Trovafloxacin, (TRO) and Ceftriaxone (CFT) in Cirrhotic Rats

- with Pneumococcal Pneumonia. First International Symposium on Pneumococci and Pneumococcal Diseases 1998, Copenhagen, Denmark.
101. Hickmon SG, Nelson CL, Skinner RA, **Olsen K**. Treatment of Experimental Osteomyelitis with Calcium Sulfate Pellets Containing Tobramycin Sulfate. Society for Biomaterials 1998, San Diego, California.
 102. Hickmon SG, Nelson CL, Skinner RA, **Olsen K**. Treatment of Experimental Osteomyelitis with Calcium Sulfate Pellets Containing Tobramycin Sulfate. Can Orthopaed Res Soc 1998.
 103. Phillips JO, Metzler MH, Huckfeldt RE, **Olsen KM**. A Multicenter, Prospective, Randomized Clinical Trial of Continuous Infusion I.V. Ranitidine vs. Omeprazole Suspension in the Prophylaxis of Stress Ulcers. Crit Care Med 1998;26(Suppl 1):A101.
 104. Rupp ME, **Olsen KM**, Bergman KL, Peddicord TE, Fey PD. Comparative Study of Bactericidal Activity and Post-antibiotic Effect (PAE) of Physiological Levels of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin against Clinical Isolates of Haemophilus influenzae. 4th International Conference on Macrolides, Azalides, and Streptogramins 1998; 4:10.03A, Barcelona, Spain.
 105. Preheim LC, Mei Y, Snitily MU, **Olsen KM**. Comparison of Azithromycin (AZI), Trovafloxacin (TRO), and Ceftriaxone (CFT) for Pneumococcal (PNC) Pneumonia in Ethanol-Fed Rats. 4th International Conference on Macrolides, Azalides, and Streptogramins 1998; 4:10.05A, Barcelona, Spain.
 106. Peddicord TE, **Olsen KM**. Effect of Immunological Modulators on *In Vitro* Penetration across Endothelial-Epithelial Cell Layers. Internat Pharmaceut Abs 1997;34(21):2228(3412647-A).
 107. Hickmon SG, Skinner RA, Nelson CL, et al #6. Efficacy of Treatment of Experimental Osteomyelitis with Calcium Sulfate Pellets Containing Tobramycin. Orthopaedic Research Society 1997.
 108. Hickmon SG, Smeltzer MS, **Olsen KM**, Nelson CL. Elution of Tobramycin from Calcium Sulfate Beads. Musculoskeletal Infection Society 1997; Snowmass, Colorado.
 109. Peddicord TE, Collier DS, **Olsen KM**. DNA Synthesis of Mononuclear Cells Exposed to Lansoprazole, Omeprazole, and Ranitidine. Clin Pharmacol Therapeut 1997; 61:169.

110. **Olsen KM**, Peddicord San Pedro GS, Peddicord TE, Monaghan MS, Jagannath S, Grayson CR. Infections in Bone Marrow Transplant Recipients Admitted to the Intensive Care Unit. *Pharmacotherapy* 1996, 16(3):A37.
111. Jing C, Peddicord TE, **Olsen KM**, Sakurada B, and Garvin K. Pharmacoeconomic Evaluation of Vancomycin-Serum Levels in Osteomyelitis Patients. The Twenty Second Annual Midwest Pharmacy Residents Conference Program 1996; pp 21. Omaha, Nebraska.
112. Collier D, Bernstein B, Peddicord TE, et al #8. Single Dose versus Multiple Dosing of Tobramycin in Liver Transplant Patients. The Twenty Second Annual Midwest Pharmacy Residents Conference Program 1996;pp 34.
113. Peddicord TE, Dahm S, Rupp ME, et al #6. Single Dose versus Multiple Dosing of Tobramycin in Critical Care Patients. The Twenty Second Annual Midwest Pharmacy Residents Conference Program 1996; pp27.
114. Peddicord TE, **Olsen KM**, Campbell GD, Jr, Rupp ME. Anti-Pseudomonal Effects of Lidocaine in Bronchial Washings and Bronchoalveolar Lavage. *Am J Resp Crit Care Med* 1996; 153(4):A562.
115. **Olsen KM**, San Pedro G, Gann LP, Halinski D, Gubbins PO, Campbell, Jr. DM. Pulmonary pharmacokinetics of azithromycin. 3rd International Conference on Macrolides, Azalides, and Streptogramins 1996, Lisbon, Portugal, Abstract #P1.
116. Peddicord TE, Zumbrunnen T, Warner, DM, **Olsen KM**. Stability of High Concentration Dopamine Hydrochloride, Norepinephrine Bitrate, Epinephrine Hydrochloride, and Nitroglycerin in Dextrose 5% and Water. (P363-R) *International Pharmaceutical Abstracts* Vol. 32, No. 21, Nov. 15, 1995.6
117. **Olsen KM**, Monaghan MS, Harrell LR, Marx MA, San Pedro GS, Ackerman BA. Histamine Release Following Vancomycin Infusion in Critically Ill Patients. *Pharmacotherapy* 1995;15(3):368.
118. Peddicord TE, ZumBrunnen T, Warner DJ, **Olsen KM**. Stability of High Concentration Dopamine Hydrochloride, Norepinephrine Bitrate, Epinephrine Hydrochloride, and Nitroglycerin in Dextrose 5% and Water. *Midwest Conference of Residents and Preceptors* 1995;pp 55, Rochester, Minnesota.

119. **Olsen KM**, San Pedro GS, Gann LP, et al. Concentration of Azithromycin in Pulmonary Tissues and Alveolar Macrophages in Healthy Volunteers. *Am J Respir Crit Care Med* 1995; 151(4):A475.
120. Marx MA, Monaghan MA, Evanoff GV, **Olsen KM**. Correlation of Phenytoin Protein Binding With Clinical Parameters after Renal Transplantation. *J Am Soc Nephrol* 1994; 5(3):1022.
121. Gurley BJ, Marx MA, **Olsen KM**, Comparison of Ultrafiltration and Direct Serum Injection Chromatography in Determining Phenytoin Free Fraction. *J Pharm Sci* 1994.
122. San Pedro GS, Grayson K, Jaganath S, **Olsen KM**. Infectious Outcomes of Bone Marrow Transplant Patients Admitted to the ICU: The Arkansas Experience. *Chest* 1994; 106:101s.
123. Monaghan MS, Ackerman BH, **Olsen KM**, et al. Pharmacokinetic Analysis of Isopropanol and Acetone using Proton Nuclear Magnetic Resonance: Comparison with Gas Chromatography. *Pharmacotherapy* 1994; 14(3):373.
124. Hickmon SG, Skinner RA, **Olsen KM**, et al. Effect of Different Gentamicin Dosing Regimens on Cure Rates in Experimental Osteomyelitis. *Transactions of the Orthopaedic Research Society* 1994;19(2):20-4.
125. Marx MA, **Olsen KM**, Monaghan MS, et al. The Effect of Renal Transplantation on Phenytoin Protein Binding. *Pharmacotherapy* 1993;13:686
126. Marx MA, **Olsen KM**, Evanoff G. The Influence of Renal Replacement Therapy on the Protein Binding of Phenytoin. *J Am Soc Nephrol* 1993;4(3):948.
127. Hearsh-Holmes M, San Pedro G, **Olsen KM**, et al. Soluble Interleukin-2 Receptor (sIL2R) Levels in Bronchoalveolar Lavage. *Chest* 1993;104(Suppl):5S.
128. Monaghan MS, **Olsen KM**, Ackerman BH, et al. Measurement of Serum Isopropanol and the Acetone Metabolite by Magnetic Resonance Imaging: Comparison with Gas Chromatography in a Simulated Overdose Model. *Pharmacotherapy* 1993; 13:294.
129. Hickmon SG, Skinner RA, Boswell RB, **Olsen KM**. Comparison of Gentamicin Dosing Regimens in the Treatment of Experimental Osteomyelitis. *Proceedings of the Musculoskeletal Infection Society*.1993; 3:7.

130. Cone JB, Wallace BH, Caldwell FT, **Olsen KM**. Burn Injury Alters the Pharmacokinetics of Enteral Ibuprofen. Proceedings of the American Burn Association 1993; 25:49.
131. Winstead S, Parr MD, King K, **Olsen KM**. Development and Implementation of a Small Volume Infusion Policy. Inter Pharmaceut Abs 1993; 30:136.
132. Davis GA, Gurney BJ, Monaghan MS, **Olsen KM**. Stability of Flumazenil in the Presence of Agents Given by Continuous Infusion. Inter Pharmaceut Abs 1993; 30:208.
133. **Olsen KM**, Kearns GL, Kemp S. Effect of Glyburide on Phenytoin Protein Binding in Elderly Patients. Pharmacotherapy 1992; 12:263.
134. **Olsen KM**, Gann LP, Anderson PJ, Marx MA, Ackerman BH, Hiller FC. Effect of Histamine₂ Receptor Antagonists on Nicotine Clearance in Smokers. Clin Pharmacol Therapeut 1992; 51:25.
135. Barnes ER, Monaghan MS, Hiller FC, **Olsen KM**. Effect of Plasma Exchange on Phenytoin Plasma Concentrations in a Morbidly Obese Patient. Midwest Conference of Residents and Preceptors, pp 40-41. Minneapolis, Minnesota, April 1991.
136. **Olsen KM**, Hiller FC, Crisp K, et al. Effect of Single Dose Histamine Receptor Antagonists on Gastric pH and Volume in Critically Ill Patients. Pharmacotherapy 1991; 11:286.
137. Falls L, Monaghan M, **Olsen KM**. Cytochrome P-450 Enzyme Inhibition and Potential Drug Interactions in Intensive Care Units. Midwest Conference of Residents and Preceptors, pp 26. Minneapolis, Minnesota, April 1991.
138. Cozart GS, Kemp B, **Olsen KM**, et al. Efficacy of Total Parenteral Nutrition in Supplying Energy Requirements of Hospitalized Patients. Midwest Conference of Residents and Preceptors, pp 67-68. Minneapolis, Minnesota, April 1991.
139. **Olsen KM**, Gann LP, Ackerman BA, et al. Rifampin Bioavailability Following Rectal Administration. Am Rev Resp Dis 1991; 143:A120.
140. MacIntyre J, Emmanuel George, Wedel NI, et al the XOMA Sepsis Study Group (includes **Olsen KM**). E5 Antibody Improves Outcomes from Multi-Organ Failure in Survivors of Gram-Negative Sepsis. Crit Care Med 1991.

141. Patrick C, **Olsen KM**, Gann LP, et al. Comparison of Nicotine Concentrations Obtained from Four Different Administration Techniques. ASHP - Student Research Forum. Midyear Clinical Meeting, Las Vegas, Nevada, December 1990.
142. **Olsen KM**, Haas FD, Pablo CS, Brian E, Gurley BJ, Ackerman BH. Effect of Liquid H₂ Antagonists on Gastric Volume and pH During Anesthesia. *Pharmacotherapy* 1991; 11:103.
143. Goad DL, Davis CM, Liem P, **Olsen KM**. The Use of Selegiline in Alzheimer's Patients with Behavior Problems. *Pharmacotherapy* 1991; 11:110.
144. Haas FD, Pablo CS, Brian JE, **Olsen KM**. The Effect of Liquid H₂ Antagonists on Gastric Volume and pH. *Anesthesiology*, 1990; 73(3A):A29.
145. Farmer E, Ackerman BH, **Olsen KM**, et al. Acute Isopropanol Intoxication: Serial Determinations of Serum Isopropanol and Acetone. *Am Soc Clin Pathol*, 1990.
146. Ramaprasad S, Campbell D, Blaszcak L, **Olsen K**. In vivo ¹⁹F NMR spectroscopy and imaging of trifluoromethyl penicillin V in rats. Society of Magnetic Resonance in Medicine. New York, NY, August 1990.
147. Haas FD, Pablo C, Brian JE, **Olsen KM**. The Effect of Cimetidine, Ranitidine, Famotidine, Sodium Citrate and Placebo on Gastric Volume and pH in Patients Undergoing Elective Surgical Procedures. Southern Research Conference for Anesthesiology Residents. May 1990.
148. Hall CR, **Olsen KM**, Gann L, et al. The Effect of Histamine₂ Antagonists on Nicotine Clearance in Smokers. Midwest Conference of Residents and Preceptors. May 1990
149. Ackerman BH, **Olsen KM**, Pappas AA. Disposition of Isopropanol Following Acute Ingestion in Adults. *Pharmacotherapy* 1990;10:256.
150. Ackerman BH, Wyeth RP, Ngo L, et al #5. Disposition of Atrial Natriuretic Factor and a Prohormone Peptide in Exercised Humans. *Pharmacotherapy* 1990; 10:243.
151. Ma FH, **Olsen KM**, Edrington D, et al. Effect of Whole Bowel Irrigation on Salicylate Absorption: A Comparison against Standard Means of Gastrointestinal Decontamination. *Pharmacotherapy* 1990; 10:256.

152. Ackerman BH, **Olsen KM**, Pappas AA. Quinidine among Patients with Inducible yet Unresponsive and Drug-Suppressed Arrhythmias. *Pharmacotherapy* 1990; 10:245.
153. **Olsen KM**, Ma FH, Gurley BJ, et al. Comparison of Fluid Volumes with Whole Bowel Irrigation in a Simulated Overdose. *Pharmacotherapy* 1990;10:256.
154. Ackerman BH, **Olsen KM**, Pappas AA. Accumulation of 3-Hydroxyquinidine among Arrhythmia Patients Treated With Chronic Quinidine. *Pharmacotherapy* 1990; 10:245.
155. Ackerman BH, **Olsen KM**, Pappas AA. Disposition of Dihydroquinidine Among Patients Receiving Parenteral Quinidine *Pharmacotherapy* 1990; 10:245.
156. Erbland ML, **Olsen KM**, Gann LP, et al. Comparison of Plasma Nicotine Concentrations Obtained From a New Cigarette Device and Conventional Cigarettes. *Am Rev Resp Dis* 1990; 140:A.
157. Herrmann D, **Olsen KM**, Gann LP, Hiller FC. Nicotine Absorption in Human Lung Tissue. *Am Rev Resp Dis* 1990; 140:A.
158. Blaszczyk L, Campbell GD, Ramaprashad S, **Olsen KM**. Fluorine Nuclear Magnetic Resonance Spectroscopy and Imaging of Antibiotics in Rats. American Society of Microbiology May 1990. Anaheim, California.
159. Saltiel E, **Olsen KM**. E5 Pharmacokinetics and Clinical Use. ACCP Symposium: E5: A Monoclonal Antibody for the Treatment of Gram-Negative Sepsis. Pittsburgh, PA October, 1989.
160. Geurian K, **Olsen KM**, Ackerman BH. Evaluation of a Clinical Pharmacokinetic Service in a University Hospital. Southeastern Society of Hospital Pharmacists. September 1989, Little Rock, Arkansas.
161. Gorelick K, Jacobs R, Chmel H, Trenholme G, Greenman R, and the Xoma Sepsis Study Group (includes **Olsen KM**). Efficacy Results of a Randomized Multicenter Trial of E5 Antiendotoxin Monoclonal Antibody in Patients with Suspected Gram-Negative Sepsis. ICCAC. September 19, 1989, Houston, Texas.
162. Martin MA, Wenzel RP, Gorelick, and the Xoma Sepsis Study Group (includes, **Olsen KM**). Prospective National Study of Gram-Negative Bacterial (GNB)

- Sepsis -Natural History in the 1980s. ICCAC, September 18, 1989, Houston, Texas.
163. Bernard GR, Grossman JE, Campbell GD, Gorelick KJ and the Xoma Sepsis Study Group (includes **Olsen KM**). Multicenter Trial of a Monoclonal Antiendotoxin Antibody (Xomen™-E5) in Gram Negative Sepsis. World Congress on Diseases of the Chest. November 1, 1989, Boston, Massachusetts.
 164. **Olsen KM**, Pablo CS, Ackerman BH. Reversal of the Central Effects of Versed (midazolam) by Intravenous Flumazenil (RO 15-1788) or Placebo After General Anesthesia in Patients Pre-medicated With Fentanyl or Sufentanil. Internat Pharmaceut Abs 1989; 24:98.
 165. Kostic BAP, **Olsen KM**, Kearns GL, Kemp S. Effect of Type I Diabetes on Phenytoin Protein Binding in Elderly Patients. International Pharmaceutical Abstracts 1989; 24:175.
 166. **Olsen KM**, Pablo C, Ackerman BH. Postoperative Analgesic Requirements Following Flumazenil (RO 15-1788) Administration. International Pharmaceutical Abstracts 1989; 24:174.
 167. **Olsen KM**, Gram Negative Bacillary Sepsis: An Overview. Internat Pharmaceut Abs 1989; 24:29.
 168. Crisp K, **Olsen KM**, Hiller FC. Effect of Cimetidine, Famotidine, and Ranitidine on Gastric Secretion in Critically Ill Patients. Midwest Conference of Residents and Preceptors. May 1989. Houston, Texas.
 169. Burch S, Erbland M, **Olsen KM**, et al. Effect of Particle Size on Nicotine Absorption. Am Rev Respir Dis. 1989; 139:A339.
 170. Herrmann D, **Olsen KM**, Hiller FC. Nicotine Absorption Following Pulmonary Instillation. Am Rev Resp Dis. 1989; 139:A334.
 171. **Olsen KM**, McCabe BJ. Assessment of Nutrition Knowledge and Attitudes of Pharmacy and Medical Students. American Association of Colleges of Pharmacy, Chicago, IL July 1988.
 172. Ackerman BH, Taylor KM, **Olsen KM**, et al. Vancomycin Serum Protein Binding Determination by Ultrafiltration. Pharmacotherapy. 1988; 7(2):2.

173. Ackerman BH, **Olsen KM**, Kennedy E, et al. Comparison of Disposition Parameters Obtained by Two Assay Methods for Quinidine Gluconate in Patients with Sustained Ventricular Tachycardia. *Pharmacotherapy* 1988; 8:118(#3).
174. Ackerman BH, **Olsen KM**, Kennedy E, et al. Disposition of 3- Hydroxyquinidine in Patients Receiving Initial Intravenous Quinidine Gluconate for Electrophysiology Testing of Ventricular Tachycardia. *Pharmacotherapy* 1988; 8:118(#22).
175. Patrick CA, **Olsen KM**, McCabe BJ. Nutrition Knowledge, Attitudes, and Behaviors of Third and Fifth Year Pharmacy Students. American Dietetic Association. Atlanta, Georgia October, 1987.
176. Ackerman BH, Olsen, KM, Taylor EH. Vancomycin Serum Protein Binding Determination by Ultrafiltration. *Drug Intel Clin Pharm* 1987; 21:4A.
177. **Olsen KM**, Latman NL. Correlation of Personality Factors with First Pharmacy Job Choice. Am Assoc Col Pharm, Toronto, Canada, July 14, 1986.
178. Stiles ML, Allen LV, **Olsen KM**, Barton CI. Augmentin Stability in Plastic Syringes. Interna Pharmaceut Abst. New Orleans, Louisiana, December 1985.
179. **Olsen KM**, Barton CI, Coniglione TC. Response of Platelets to Parenteral Iron Dextran in Reactive Thrombocytosis. International Pharmaceut Abst December 1985.
180. **Olsen KM**, DuBe' JE. The Development and Evaluation of Steroid Education Programs: Comparison of Written and Audio-visual Aides. Intern Pharmaceut Abs, December 1982.

LETTERS

1. **Olsen KM**, Barton CI. Cost Benefits of Patient Education. Letter. *Am Pharm* 1985; 25(6):331.
2. Frye CB, **Olsen KM**. Preparation of an Oral Lavage Solution for Bowel Cleansing. Letter. *Am J Hosp Pharm* 1985; 42:278-279.
3. **Olsen KM**. Stress-Induced Analgesia. Book Review. *Am J Pharm Ed* 1985; 49:231.

4. Chen BH, Taylor EH, Ackerman BH, **Olsen KM**. Influence of Serum pH on the Ultrafiltration Determination of Free Quinidine. *Ann Pharmacother* 1988; 22:826.
5. O'Neill K, Hurt B, **Olsen K**, et al. Variance in Quinidine Maintenance Dose Prediction Using Four Dosing Methods. *Ther Drug Monit* 1989;11:487-488.
6. Ackerman BH, **Olsen KM**, Butterworth C. Errors in Assuming a One Compartment Model for Vancomycin. *Ther Drug Monit* 1990; 12:304-305.
7. Ackerman BH, **Olsen KM**, Pappas AA. Accumulation of 3-Hydroxyquinidine Following Chronic Quinidine Therapy. *Ann Pharmacother* 1991; 25:867-869.
8. Fuller PD, **Olsen KM**: Clinical Twisters: Reducing risk of infection. 2002;116: Drug Topics HSE16. (Invited commentary)
9. Devlin JW, **Olsen KM**. Proton Pump Delivery Methods. *Annals of Pharmacotherapy* 2006;4.